document incorporate reference specify portion registrant proxy statement file commission pursuant regulation connection registrant annual meeting stockholder hold incorporate reference iii report base closing price share june exclude share registrant common stock hold executive officer director stockholder ownership exceed registrant common stock outstanding june exclusion share construe indicate person possess power direct indirect direct cause direction management policy registrant person control common control registrantgilead sciences inc annual report table content item business item risk factor item b unresolved staff comment item property item legal proceeding item safety disclosure ii item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure item b information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service iv item exhibit financial statement schedule item summary signature right trademark copyright trade name business include follow gilead gilead science ambisome atripla biktarvy cayston complera descovy descovy prep emtriva epclusa eviplera genvoya harvoni hepsera jyseleca letairis odefsey ranexa sovaldi stribild tecartustm trodelvy truvada truvada prep tybost veklury vemlidy viread vosevi yescarta zydelig lexiscan register trademark astella llc macugen register trademark bausch health ireland limited symtuza register trademark janssen sciences ireland unlimited company tamiflu register trademark hoffmannla roche inc hepcludex register trademark myr gmbh report refer trademark service mark trade name companiesthis annual report include section entitle management discussion analysis financial condition result operation contain forwardlooke statement future event future result subject safe harbor create security act amend securities act securities exchange act amended exchange act word expect anticipate target goal project hope intend plan believe seek estimate continue forecast variation word similar expression intend identify forwardlooke statement addition statement statement historical fact forwardlooke statement include statement overall trend operate cost revenue trend liquidity capital need collaboration licensing arrangement ongoing litigation investigation matter statement anticipate future impact business ongoing coronavirus disease covid relate public health measure statement development manufacture distribution veklury treatment covid statement expectation belief future plan strategy anticipate event trend similar expression base forwardlooke statement current expectation future event statement guarantee future performance involve risk uncertainty assumption difficult predict actual result differ materially suggest forward look statement reason include identify item annual report head risk factor give risk uncertainty caution place undue reliance forwardlooke statement forwardlooke statement include report date hereof require federal security law rule regulation securities exchange commission sec undertake specifically decline obligation update statement publicly announce result revision forwardlooke statement distribution report result new information future event change assumption item business gilead sciences inc gilead biopharmaceutical company pursue achieve breakthrough medicine decade goal create healthy world people commit advance innovative medicine prevent treat lifethreatening disease include hiv viral hepatitis cancer operate country worldwide headquarters foster city california business product innovative medicine represent advancement offer firstinclass treatment great efficacy enhance mode delivery convenient treatment regimen improve resistance profile reduce effect focus innovation allow deliver market product multiple therapeutic area primary revenuegenerating product approve indication united states follow hivaids biktarvy oral formulation dose day treatment hiv infection certain patient biktarvy single tablet regimen fixeddose combination antiretroviral medication bictegravir emtricitabine tenofovir alafenamide taf genvoya oral formulation dose day treatment hiv infection certain patient genvoya single tablet regimen fixeddose combination antiretroviral medicine elvitegravir cobicistat emtricitabine taf descovy oral formulation indicate combination antiretroviral agent treatment hiv infection certain patient descovy fixeddose combination antiretroviral medication emtricitabine taf descovy approve food drug administration fda preexposure prophylaxis prep indication reduce risk sexually acquire hiv infection certain atrisk patient odefsey oral formulation dose day treatment hiv infection certain patient odefsey single tablet regimen fixeddose combination antiretroviral medication emtricitabine taf rilpivirine market janssen sciences ireland unlimited company janssen pharmaceutical companies johnson johnson janssen truvada oral formulation indicate combination antiretroviral agent treatment hiv infection certain patient fix dose combination antiretroviral medication tdf emtricitabine truvada approve fda prep indication reduce risk sexually acquire hiv infection certain atrisk patient compleraeviplera oral formulation dose day treatment hiv infection certain patient product market united states complera europe eviplera single tablet regimen fixeddose combination antiretroviral medication tenofovir disoproxil fumarate tdf emtricitabine janssen rilpivirine hydrochloride stribild oral formulation dose day treatment hiv infection certain patient stribild single tablet regimen fixeddose combination antiretroviral medication elvitegravir cobicistat tdf emtricitabine atripla oral formulation indicate complete regimen treatment hiv infection certain patient atripla fixeddose combination antiretroviral medication tdf emtricitabine bristolmyers squibb company bmss efavirenz covid veklury remdesivir injection intravenous use nucleotide analog rna polymerase inhibitor indicate certain patient treatment coronavirus disease covid require hospitalization liver disease epclusa oral formulation oncedaily single tablet regimen sofosbuvir velpatasvir treatment chronic hepatitis c virus hcv infection adult certain pediatric patient genotype cirrhosis compensate cirrhosis ii decompensate cirrhosis use combination ribavirin addition authorize generic version epclusa distribute separate subsidiary asegua therapeutics llc harvoni oral formulation oncedaily single tablet regimen ledipasvir sofosbuvir treatment chronic hcv infection adult genotype cirrhosis compensate cirrhosis ii adult genotype infection decompensate cirrhosis combination ribavirin iii adult genotype liver transplant recipient cirrhosis compensate cirrhosis combination ribavirin iv certain pediatric patient genotype cirrhosis compensate cirrhosis addition authorize generic version harvoni distribute separate subsidiary asegua therapeutics llc vosevi oral formulation oncedaily single tablet regimen sofosbuvir velpatasvir voxilaprevir retreatment chronic hcv infection adult genotype previously treat nsa inhibitorcontaine regimen ii genotype previously treat sofosbuvircontaine regimen nsa inhibitor vemlidy oral formulation taf dose day treatment chronic hepatitis b virus hbv infection adult compensate liver disease viread oral formulation tdf dose day treatment chronic hbv infection adult certain pediatric patient hematologyoncologycell therapy yescarta axicabtagene ciloleucel suspension intravenous infusion chimeric antigen receptor car cell therapy treatment adult patient relapse refractory large bcell lymphoma line systemic therapy include diffuse large bcell lymphoma dlbcl specify primary mediastinal large bcell lymphoma highgrade bcell lymphoma dlbcl arise follicular lymphoma tecartus brexucabtagene autoleucel suspension intravenous infusion car cell therapy treatment adult patient relapse refractory mantle cell lymphoma trodelvy sacituzumab govitecanhziy injection intravenous use trop direct antibody topoisomerase inhibitor conjugate indicate treatment adult patient metastatic triplenegative breast cancer receive prior therapy metastatic disease indication approve accelerate approval fda continue approval indication contingent verification description clinical benefit confirmatory trial zydelig idelalisib oral formulation kinase inhibitor treatment patient relapse chronic lymphocytic leukemia cll combination rituximab rituximab consider appropriate therapy comorbidities ii relapse follicular bcell non hodgkin lymphoma fl patient receive prior systemic therapy iii relapse small lymphocytic lymphoma receive prior systemic therapy letairis ambrisentan oral formulation endothelin receptor antagonist treatment pulmonary arterial hypertension pah group improve exercise capacity delay clinical worsen ii combination tadalafil reduce risk disease progression hospitalization worsen pah improve exercise ability ranexa ranolazine oral formulation extendedrelease tablet antianginal treatment chronic angina ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treatment invasive fungal infection cause fungal specie adult information revenuegenerate product include revenue contribute product list note revenue note consolidated financial statement include ii item annual report revenue share revenue generate revenue activity include revenue share combination product royaltie outbound license intellectual property payment receive collaboration thirdparty partner example pursuant collaboration janssen receive revenue share cobicistat emtricitabine taf components symtuza darunavircobicistatemtricitabinetaf fixeddose combination product commercialize janssen include revenue share symtuza product sale description collaboration janssen partner note collaboration arrangement note consolidated financial statement include ii item annual report form k commercialization distribution international commercial sale operation marketing subsidiary country product market commercial team andor conjunction thirdparty distributor corporate partner commercial team promote product direct field contact physician hospital clinic healthcare provider generally grant thirdparty distributor exclusive right promote product territory specify period time agreement distributor provide collaborative effort distributor gilead obtain maintain regulatory approval product specify territory sell distribute product united states exclusively wholesale channel month end december approximately product sale united states approximately total worldwide revenue large wholesaler amerisourcebergen corporation cardinal health inc mckesson corporation sell distribute product europe country outside united states product approve commercial team thirdparty distributor corporate partner competition operate highly competitive environment face significant competition global pharmaceutical biotechnology company specialize pharmaceutical firm generic drug manufacturer product compete commercially available product base primarily efficacy safety tolerability acceptance doctor ease patient compliance ease use price insurance reimbursement coverage distribution marketing product mature private insurer government payer reduce reimburse patient increase pressure reduce price new brand generic product introduce major market ability maintain pricing market share affect research development research development rd mission discover develop transformational therapy area high unmet medical need product development effort focus primarily viral disease inflammatory disease oncology team research scientist engage discovery development new molecule technology hope lead approval innovative medicine therapy advance current standard care address unmet medical need intend continue commit significant resource internal rd opportunity external business development activity drive innovation growth business development product candidate investigational therapy pipeline subject risk uncertaintie risk uncertainty include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain regulatory approval result product candidate investigational therapy successfully commercialize drug development inherently risky product candidate investigational therapy fail development process continue invest advance rd pipeline therapeutic area summary product candidate phase registrational phase clinical trial pende marketing authorization review fda european medicines agency ema product candidate viral disease product candidate description phase phase remdesivir injection remdesivir injection evaluate outpatient treatment covid expand indication lenacapavir lenacapavir hiv capsid inhibitor evaluate component longacte regimen treatment hiv infection heavily treatmentexperience people live hiv grant breakthrough therapy designation fda indication bulevirtide bulevirtide evaluate treatment chronic hepatitis delta virus hdv infection grant orphan drug breakthrough therapy designation fda chronic hdv infection grant breakthrough therapy designation priority medicine prime scheme eligibility european commission chronic hdv infection december enter definitive agreement acquire myr gmbh closing subject regulatory clearance condition acquisition provide hepcludex bulevirtide conditionally approve european commission treatment chronic hdv infection july product candidate inflammatory disease product candidate description regulatory filing filgotinib marketing authorization application file ema filgotinib jak inhibitor treatment ulcerative colitis phase filgotinib filgotinib evaluate treatment crohns disease cilofexor cilofexor fxr agonist evaluate treatment primary sclerose cholangitis product candidate oncology product candidate description regulatory filing axicabtagene ciloleucel supplemental biologics license application axicabtagene ciloleucel car cell therapy treatment relapse refractory indolent nonhodgkin lymphoma inhl file fda grant breakthrough therapy designation fda inhl indication brexucabtagene autoleucel brexucabtagene autoleucel car cell therapy receive accelerated approval fda conditional marketing authorization european commission treatment adult patient relapse refractory mantle cell lymphoma line systemic therapy include bruton tyrosine kinase inhibitor conditional marketing authorization europe initially valid year extend convert unconditional authorization submission assessment additional confirmatory datum sacituzumab govitecanhziy supplemental biologic license application approval sacituzumab govitecanhziy trop direct antibody topoisomerase inhibitor conjugate treatment patient metastatic triplenegative breast cancer mtnbc receive prior therapy file fda grant breakthrough therapy designation fda mtnbc indication sacituzumab govitecanhziy supplemental biologic license application accelerate approval sacituzumab govitecanhziy treatment heavilypretreate patient metastatic urothelial cancer file fda phase axicabtagene ciloleucel axicabtagene ciloleucel evaluate treatment second line diffuse large b cell lymphoma magrolimab magrolimab anticd evaluate treatment myelodysplastic syndrome mds grant breakthrough therapy designation fda prime scheme eligibility european commission mds indication sacituzumab govitecanhziy sacituzumab govitecanhziy evaluate treatment hormone receptor positive hr human epidermal growth factor receptor negative metastatic breast cancer patient fail prior chemotherapy regimen registrational phase brexucabtagene autoleucel brexucabtagene autoleucel car cell therapy evaluate treatment adult acute lymphoblastic leukemia grant breakthrough therapy designation fda adult indication brexucabtagene autoleucel brexucabtagene autoleucel car cell therapy evaluate treatment pediatric grant breakthrough therapy designation fda pediatric indication magrolimab magrolimab evaluate treatment diffuse large b cell lymphoma seek add portfolio product product candidate acquisition inlicense strategic collaboration enter strategic partnership acquisition enhance commercial portfolio clinical pipeline multiple therapeutic area example acquisition immunomedics inc immunomedics add trodelvy pipeline program oncology portfolio strategic business development activity reflect commitment focus transformative science build sustainable diverse portfolio position near medium longterm growth business patent proprietary right european patent expiration number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent follow table show estimate expiration date include patent term extension supplementary protection certificate andor pediatric exclusivity grant united states european union primary typically compound patent key product candidate describe product candidate fixeddose combination single tablet regimen estimate patent expiration date provide correspond late expiring compound patent active ingredient single tablet regimen key product candidate patent expiration eu viral disease remdesivir lenacapavir bulevirtide inflammatory disease filgotinib cilofexor oncology axicabtagene ciloleucel brexucabtagene autoleucel sacituzumab govitecanhziy magrolimab december enter definitive agreement acquire myr gmbh closing subject regulatory clearance condition acquisition provide bulevirtide composition matter patent expire european union european union united states patent application pende relate proprietary manufacturing process kite gilead company kite application patent term extension file united states grant extend expiration date regulatory exclusivity united states expire follow table show actual estimate expiration date include patent term extension supplementary protection certificate andor pediatric exclusivity grant united states european union primary typically compound patent principal product product fixeddose combination single tablet regimen estimate patent expiration date provide correspond late expiring compound patent active ingredient single tablet regimen product patent expiration eu ranexa atripla truvada descovy vemlidy compleraeviplera zydelig odefsey yescarta stribild genvoya harvoni epclusa biktarvy vosevi veklury tecartus trodelvy jyseleca hepcludex estimate expiration date include potential additional exclusivity eg patent term extension supplementary protection certificate pediatric exclusivity grant gilead lupin limit reach agreement settle patent litigation matter relate ranexa gilead teva pharmaceuticals teva reach agreement settle patent litigation concern patent protect emtricitabine truvada atripla product pursuant teva permit launch generic fixeddose combination emtricitabine tdf generic fixeddose combination emtricitabine tdf efavirenz united states september supplementary protection certificate spc grant european country validity spc challenge generic manufacturer launch compete product application patent term extension pende united states andor spc pende country european union product composition matter patent expire european union european union united states patent application pende relate proprietary manufacturing process kite gilead mylan pharmaceutical reach agreement settle patent litigation concern patent protect cobicistat stribild genvoya product application patent term extension file united states grant extend expiration date regulatory exclusivity united states expire december enter definitive agreement acquire myr gmbh closing subject regulatory clearance condition acquisition provide hepcludex bulevirtide conditionally approve european commission treatment chronic hdv infection july bulevirtide approve fda use safety efficacy establish patent protection certain challenge patent proprietary right important business properly draft enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology patent cover certain active pharmaceutical ingredient api hiv product cell therapy product hold party acquire exclusive right patent agreement party obtain patent certain product year marketing approval obtain patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension supplementary protection certificate country example extension patent supplementary protection certificate product grant united states number european country compensate delay obtain marketing approval similar patent term extension available product develop certain obtain country important infringe valid patent party infringe valid patent party reputation harm require pay significant monetary damage prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product example aware patent patent application own party party claim cover use sofosbuvir axicabtagene ciloleucel brexucabtagene autoleucel tenofovir disoproxil tenofovir alafenamide bictegravir patent application confidential period time patent issue know competitor file patent application technology cover pende application invent file application direct technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete product addition competitor file patent application cover technology participate interferencederivation proceeding litigation determine right patent litigation interferencederivation proceeding unpredictable expensive ultimately successful result operation adversely affect event patent relate pharmaceutical biopharmaceutical biotechnology product compound process cover exist compound product process likely file future provide complete adequate protection future litigation proceeding enforcement validity exist patent future patent result invalidation patent substantially reduce protection time time certain individual entity challenge patent pende patent application patent application file collaborative partner result issuance patent result patent provide adequate protection result able prevent party develop compound product closely relate developed develop addition certain country provide effective enforcement patent thirdparty manufacturer able sell generic version product country description significant pende legal proceeding note commitment contingency note consolidated financial statement include ii item annual report item risk factor success depend significant degree ability obtain defend patent intellectual property right domestically internationally operate infringe patent proprietary right party trade secret rely unpatented trade secret improvement unpatente internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor rd agreement invention jointly own corporate partner case exclusive property party certain circumstance difficult determine own particular invention dispute arise invention trade secret confidential information know independently discover competitor enter dispute ownership invention business result operation adversely affect manufacture raw material product manufacture facility thirdparty contract manufacturer depend party perform manufacturing activity majority api drug product product include hiv hcv product use multiple thirdparty contract manufacturer primary backup supplier manufacturing site cell therapy product establish clinical commercial manufacturing facility cell processing activity future product continue develop additional manufacturing capability establish additional thirdparty supplier manufacture sufficient quantity product candidate undertake clinical trial manufacture sufficient quantity product approve commercial sale manufacturing facility lease manufacturing facility manufacture distribute certain product api clinical andor commercial use facility locate foster city san dimas la verne oceanside el segundo california morris plain new jersey dublin cork ireland hoofddorp netherlands edmonton canada foster city california conduct process chemistry research formulation development activity manufacture api drug product clinical trial oversee thirdparty contract manufacturer san dimas la verne california manufacture ambisome package label majority commercial product distribution america pacific rim oceanside california utilize facility clinical manufacturing process development biologic candidates el segundo california utilize facility clinical commercial manufacturing processing cell therapy product morris plain new jersey utilize facility commercial manufacturing process optimization antibody drug conjugate product cork dublin ireland utilize cork facility commercial manufacturing packaging labeling product perform quality control testing labeling package final release product cork facility distribute european union international market facility dublin utilize facility central dublin drug development hub pediatric program perform clinical development safety quality biostatistic datum science regulatory compliance function edmonton canada conduct process chemistry research scaleup activity clinical development candidate manufacture api investigational commercial product conduct chemical development activity improve exist commercial manufacturing process hoofddorp netherland utilize facility commercial manufacturing processing cell therapy product thirdparty manufacturer believe technology use manufacture product proprietary product manufacture thirdparty contract manufacturer disclose necessary aspect technology enable manufacture product agreement thirdparty manufacturer intend restrict reveal technology certain thirdparty manufacturer comply restriction information thirdparty manufacturer item risk factor face manufacture difficulty delay interruption include thirdparty manufacturer corporate partner regulation manufacturing process manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation thirdparty manufacturer corporate partner subject current good manufacturing practice extensive regulation govern manufacturing process stability testing record keep quality standard define fda european medicine agency similar regulation effect jurisdiction manufacture operation subject routine inspection regulatory agency cell therapy product require fda comply risk evaluation mitigation strategy program include educate certify medical personnel therapy procedure potential effect profile therapy potential adverse effect relate cytokine release syndrome neurologic toxicity additionally require maintain complex chain identity custody respect patient material material move manufacturing facility manufacturing process patient access raw material need access certain raw material conduct clinical trial manufacture product raw material generally available multiple source purchase worldwide normally available quantity adequate meet need business attempt manage risk associate supply chain inventory management relationship management evaluation alternative source feasible information item risk factor able obtain material supply necessary conduct clinical trial manufacture sell product limit ability generate revenue human capital gilead success depend work dedicated employee embrace share sense purpose culture excellence human capital objective gilead employer choice good talent industry gilead key priority human capital management include inclusion diversity health safety total reward employee development engagement board compensation talent committee oversee overall human capital management inclusion diversity inclusion gilead core value commit advance inclusion diversity d workforce establish global diversity council responsible governance matter track progress goal promote culture inclusion global diversity council chair chairman chief executive officer gilead implement multiple program train manager d topic build awareness drive inclusive behavior employee resource group erg support diverse employee aim raise awareness different culture workplace cultivate diversity business strength support gilead talent acquisition strategy source attract recruit diverse candidate believe gilead inclusive diverse workforce foundation innovation productivity gilead commitment equal employment opportunity further effort cultivate celebrate equitable culture belong december gilead approximately employee gilead global workforce approximately female male additionally woman represent gilead leadership define vice president level base employee voluntary selfidentification workforce white asian hispanic black health safety gilead commit provide safe healthy secure workplace employee environmental health safety policy maintain compliance program support commitment routinely train educate employee workplace safety security covid pandemic gilead site require flexible location employee work home employee need physically present position laboratory technician continue work gilead site implement site enhancement risk protocol include health screening covid testing reconfiguration work common space allow social distancing effort support safe occupancy site gilead maintain robust contact trace notification process employee report covid infection date identify case viral transmission covid workplace total reward gilead compensation benefit program design help attract cultivate retain industry talented workforce total reward program vary country include competitive base salary incentive compensation stock award employee stock purchase plan k saving plan company match vest immediately health welfare valuable benefit flexible spending account pay time family leave family care resource adoption surrogacy assistance employee assistance program global wellness reimbursement tuition assistance year reassess total reward package confirm offer benefit incentive align total reward philosophy response covid pandemic implement number temporary covidspecific benefit cost reimbursement essential home office equipment monthly reimbursement childcare homeschooling cost special pay enhancement physical location dependent worker require onsite gilead nature role support workforce unique challenge present pandemic commit address pay equity employee salary inform marketbase range assess annually performance career development review policy compensation decision regard personal characteristic gender race color national ethnic origin age disability sexual orientation gender identity expression genetic information religion veteran status conduct annual pay equity review employee compensation effort strive pay practice gender race neutral employee development engagement gilead offer number professional management leadership development training program help employee develop crossfunctional skill tool grow career addition employee receive reimbursement tuition expense incur pursue undergraduate graduate certificate course accredit college university change pursue ambition employer choice industry important consider input employee listen strategy help gather employee input measure progress conduct global survey assess improve employee retention engagement gather feedback action address area employee concern employee response survey key determine meaningful benefit relate covid pandemic direction culture go forward environmental social governance esg gilead build corporate social responsibility program continue execute mission provide lifesave medicine area unmet need additional information program esg highlight available gileads year review gilead website httpswwwgileadcomnew andpressannualreportyearinreview seasonality operation worldwide product sale reflect significant degree seasonality endus demand united states fluctuation wholesaler inventory level impact product sale typically observe strong wholesaler subwholesaler purchase product fourth quarter result inventory drawdown wholesaler subwholesaler subsequent quarter factor include government budget annual grant cycle federal state fund covid pandemic buying pattern impact product sale record particular quarter information item risk factor face challenge accurately forecast sale difficulty predict demand product fluctuation purchase pattern wholesaler inventory government regulation operation activity subject extensive regulation numerous government authority united states european union country include law regulation govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion product result regulation product development product approval process expensive time consume significant impact capital expenditure result operation regulatory requirement applicable drug development approval subject change legal regulatory change impact operation future country regulatory agency fda united states european medicines agency european commission european union national authority european union member state approve drug sell respective country country general process drug approval united states summarize country include country european union european union centralize procedure similar regulatory structure preclinical testing test drug candidate human study drug laboratory experiment animal generate datum support drug candidate potential benefit safety submit datum fda investigational new drug ind application seek approval test compound human clinical trial fda accept ind drug candidate study human clinical trial determine drug candidate safe effective clinical trial involve separate phase overlap year expensive phase subject considerable regulation follow phase drug candidate give small number healthy human control subject patient suffer indicate disease test safety dose tolerance pharmacokinetic metabolism distribution excretion phase drug candidate give limited patient population determine effect drug candidate treat disease good dose drug candidate possible effect safety risk drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous extensive phase clinical trial phase drug candidate appear effective appropriate safety profile phase clinical trial phase clinical trial commence confirm result phase clinical trial conduct long term involve significantly large population conduct numerous site different geographic region carefully design provide reliable conclusive datum safety benefit drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous extensive phase clinical trial fda approval process believe datum clinical trial acceptable benefitrisk profile submit appropriate filing usually form new drug application nda biologics license application bla supplemental application fda seek approval sell drug candidate particular use fdas discretion fda hold public hear independent advisory committee expert advisor ask additional question make recommendation drug candidate committee make recommendation fda binding generally follow fda fda agree drug meet require level safety efficacy particular use approve application allow sell drug united states use unusual fda decline approve application believe drug candidate safe efficacious ie appropriate benefit versus risk profile believe datum submit reliable conclusive point process development drug candidate stop number reason include safety concern lack treatment benefit certain clinical trial currently conduct conduct future complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk drug candidate appear sufficient treatment benefit fda require phase nonregistrational study explore scientific question characterize safety efficacy commercial use drug fda require provide additional data information improve manufacturing process procedure facility require extensive surveillance monitor safety benefit product candidate determine file contain adequate evidence safety benefit drug addition fda approve drug limit use drug fda withdraw approval believe comply regulatory standard concern safety efficacy uncover occur approval addition obtain fda approval drug obtain fda approval manufacturing facility drug sell include company manufacture drug facility subject periodic inspection fda fda approve foreign establishment manufacture product sell united states facility subject periodic regulatory inspection manufacturing facility locate california license state california compliance local regulatory requirement manufacture facilities canada ireland netherlands obtain local license permit compliance local regulatory requirement fda employ tool facilitate expedite development review drug include fast track designation breakthrough therapy designation accelerate approval priority review designation fast track designation design facilitate development review drug treat condition fill unmet medical need breakthrough therapy designation design expedite development review drug treat condition preliminary clinical evidence demonstrate substantial improvement available therapy accelerate approval drug grant fda drug treat condition fill unmet medical need study safety efficacy priority review designation mean fda goal action application month file fda grant priority review designation drug provide significant improvement safety effectiveness treatment diagnosis prevention condition european union regulatory system approval process european union eu products subject variety eu eu member state regulation govern clinical trial commercial sale distribution require obtain marketing authorization eu market medicinal product relevant market conduct clinical trial eu govern directive ec directive ec eu ich good clinical practice rule impose legal regulatory obligation similar provide applicable law conduct clinical trial eu approve competent authority eu member states clinical trial place positive opinion obtain relevant ethic committee relevant member state eu legislator adopt regulation eu replace directive ec introduce coordinated procedure authorization clinical trial regulation expect apply marketing authorization holder manufacturer importer wholesaler distributor medicinal product place market eu require comply number regulatory requirement include pharmacovigilance good manufacturing practice compliance requirement obtain manufacture import andor distribution license issue competent authority eu member states failure comply requirement lead imposition civil criminal administrative sanction include suspension marketing manufacturing authorization pricing reimbursement successful commercialization product depend availability thirdparty payer reimbursement cost product relate treatment medical service market sell product government health authority private health insurer organization generally provide reimbursement united states european union significant potentially significant market product product candidate government authority private payer increasingly attempt limit regulate price medical product service significant portion sale majority product subject substantial discount list price include rebate require pay medicaid agency discount require pay b cover entity result price increase implement time time certain product limit effect product sale certain market addition standard reimbursement structure adequately reimburse innovative therapy product mature private insurer government payer reduce reimburse provider increase pressure reduce price new brand generic product introduce major market ability maintain pricing market share affect information item risk factor exist product subject reimbursement pressure government agency party require rebate discount product pricing pressure face challenge accurately forecast sale difficulty predict demand product fluctuation purchase pattern wholesaler inventory patient assistance program recently enhance scrutiny companysponsore patient assistance program include copay assistance program manufacturer donation thirdparty charity provide assistance enhance scrutiny government reimbursement support offering clinical education program promotional speaker program agent vendor deem fail comply law regulation government guidance area subject criminal civil sanction similar violation competitor negatively impact industry reputation increase scrutiny business product health care fraud abuse law antibribery law subject federal state law pertain health care fraud abuse include antikickback law false claim law anti kickback law illegal prescription drug manufacturer knowingly willingly solicit offer receive pay remuneration exchange induce referral business reimburse federal healthcare program include purchase prescription particular drug false claim law generally prohibit knowingly present cause present false fraudulent claim payment federal certain state payer include medicare medicaid knowingly make cause false record statement material false fraudulent claim breadth statutory provision attention give law enforcement authority sale marketing patient support medical activity subject scrutiny law example recently enhance scrutiny government enforcement authority companysponsore patient assistance program include copay assistance program manufacturer donation thirdparty charity provide assistance reimbursement support offering clinical education program promotional speaker program similarly europe interaction pharmaceutical company physician subject strict law regulation industry selfregulation code conduct physician code professional conduct applicable include eu member states anticorruption law uk bribery act addition foreign corrupt practice act similar worldwide antibribery law generally prohibit company intermediary make improper payment purpose obtain retain business policy mandate compliance antibribery law operate part world experience governmental corruption degree certain circumstance strict compliance antibribery law conflict local custom practice require interact doctor hospital state control manner different local custom despite train compliance program internal control policy procedure protect unlawful act commit employee agent violation fraud abuse law antibribery law punishable criminal andor civil sanction include fine civil monetary penalty possibility exclusion federal health care program include medicare medicaid violation lead imposition corporate integrity agreement similar government oversight program similar violation competitor negatively impact reputation industry increase governmental public scrutiny business product healthcare reform federal state government continue propose pass legislation design regulate healthcare industry include legislation seeks indirectly directly regulate pharmaceutical drug pricing information item risk factor impact evolve law regulation legislative regulatory action applicable health care industry environment subject number law regulation require compliance federal state local regulation protection environment regulatory landscape continue evolve anticipate additional regulation future law regulation implement consideration mitigate effect climate change mainly cause greenhouse gas emission business energy intensive anticipate subject cap trade system mitigation measure materially impact capital expenditure operation competitive position information subject information requirement securities exchange act exchange act file periodic report proxy information statement information sec sec maintains website httpwwwsecgov contain report proxy information statement information issuer file electronically sec mailing address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors website sec filing section available follow filing free charge soon reasonably practicable electronically file furnished sec annual report quarterly report form q current report form k amendment report file furnish pursuant section exchange act website reference provide document convenience content reference website constitute incorporate reference annual report item risk factor evaluate business carefully consider follow discussion material risk event uncertainty investment speculative risky addition information annual report manifestation follow risk uncertainty circumstance able accurately predict materially adversely affect business growth reputation include commercial scientific reputation product prospect product pipeline sale operate financial result financial condition cash flow liquidity stock price note factor investor permit private security litigation reform act possible predict identify factor operation affect factor event uncertainty presently know currently consider present significant risk operation consider follow risk complete statement potential risk uncertainty face product commercialization risk certain product subject additional heighten risk hiv product receive substantial portion revenue sale product treatment prevention hiv infection month end december sale hiv product account approximately total product sale unable sustain increase sale hiv product number reason include market share gains competitive product inability introduce new hiv medication necessary remain competitive case need scale operation include future drug development spending research development rd effort example hiv product contain tenofovir alafenamide taf tenofovir disoproxil fumarate tdf andor emtricitabine ftc belong nucleoside class antiviral therapeutic change treatment paradigm hiv cause nucleosidebase therapeutic fall favor veklury remdesivir face risk relate significant investment rapid development manufacturing distribution veklury remdesivir approve food drug administration fda october treatment hospitalize patient covid give severity urgency covid pandemic commit significant capital resource clinical trial scaleup production remdesivir expect investment continue continue manufacture large quantity finish product conduct additional study specific patient population develop evaluate new formulation delivery method combination therapie utilization remdesivir largely track level infection unable accurately predict revenue supply need short long term potential new well therapeutic availability effectiveness vaccine fluctuate hospital utilization rate unable accurately forecast demand manufacture veklury level meet actual demand result shortage excess inventory write subject significant public attention scrutiny complex decision clinical datum allocation distribution pricing veklury affect corporate reputation yescarta advance novel personalize therapy yescarta chimeric antigen receptor car cell therapy create significant challenge include educate certify medical personnel procedure potential effect cytokine release syndrome neurologic toxicity compliance risk evaluation mitigation strategy program require fda secure sufficient supply medication manage effect tocilizumab corticosteroid available sufficient quantity adequately control effect andor detrimental impact efficacy yescarta develop maintain robust reliable process engineering patient cell facility infuse patient conditioning patient chemotherapy advance administer therapy increase risk adverse effect use engineer cell potential cancer treatment recent development broadly accept physician patient hospital cancer treatment center payer medical community able demonstrate medical community payer potential advantage yescarta compare exist future therapeutic challenge relate reimbursement yescarta exist product subject reimbursement pressure government agency party require rebate discount product pricing pressure rely thirdparty site collect patient white blood cell know apheresis center shipper courier hospital logistical collection patient white blood cell ultimate delivery yescarta patient vendor encounter disruption difficulty result product loss regulatory action apheresis center choose participate quality certification process unable complete certification timely manner delay constrain manufacturing commercialization effort success depend develop commercialize new product expand indication exist product unable launch commercially successful new product new indication exist product business adversely impact launch commercially successful product necessary grow business cover substantial rd expense offset revenue loss exist product lose market share factor competition loss patent exclusivity difficulty uncertaintie inherent drug development introduction new product product development cycle characterize significant investment resource long lead time unpredictable outcome nature develop medicine human use expend significant time resource product pipeline assurance recoup investment effort commercially successful high rate failure inherent discovery development new product failure occur point process include late process substantial investment face challenge accurately forecast sale difficulty predict demand product fluctuation purchase pattern wholesaler inventory unable accurately predict demand product include uptake new product demand depend number factor example product demand adversely affect physician benefit product additionally nonretail sector united states include government institution include state aids drug assistance program department veterans affair correctional facility large health maintenance organization tend consistent term buy pattern cause quarteroverquarter fluctuation necessarily mirror patient demand product federal state budget pressure annual grant cycle federal state fund cause purchasing pattern reflect patient demand product expect continue experience fluctuation purchase pattern nonretail customer light budget crisis face european country observe variation purchase pattern induce cost containment measure europe believe measure cause government agency purchaser reduce inventory product distribution channel continue trend future sell distribute product united states exclusively wholesale channel year end december approximately product sale united states wholesaler amerisourcebergen corporation cardinal health inc mckesson corporation wholesaler enter inventory management agreement estimate determine end user demand completely effective match inventory level actual end user demand result change inventory level hold wholesaler cause operating result fluctuate unexpectedly sale wholesaler match end user demand addition inventory hold retail pharmacy nonwholesaler location inventory management agreement control buy pattern adverse change economic condition increase competition factor cause retail pharmacy reduce inventory product reduce order wholesaler consequently wholesalers order end user demand change addition observe strong wholesaler subwholesaler purchase product fourth quarter typically result inventory drawdown wholesaler subwholesaler subsequent quarter inventory distribution channel fluctuate quarter quarter continue fluctuation earning mismatch prescription demand product revenue face significant competition global pharmaceutical biotechnology company specialize pharmaceutical firm generic drug manufacturer new brand generic product enter major market affect ability maintain pricing market share product compete available product base primarily efficacy safety tolerability acceptance doctor ease patient compliance ease use price insurance reimbursement coverage distribution marketing number company pursue development technology competitive exist product research program compete company include large pharmaceutical biotechnology company specialize pharmaceutical firm act independently company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program adversely impact competitor gain market share result new technology commercialization strategy exist product subject reimbursement pressure government agency party require rebate discount product pricing pressure product reimbursement successful commercialization product depend availability thirdparty payer reimbursement cost product relate treatment medical service market sell product government health authority private health insurer organization generally provide reimbursement product mature private insurer government payer reduce reimburse patient product increase pressure reduce price legislative regulatory action affect government prescription drug procurement reimbursement program occur relatively frequently example september fda issue final rule implement pathway importation certain prescription drug canada rule subject ongoing litigation addition november centers medicare medicaid services cms issue interim final rule substantially alter medicare b reimbursement system physicianadministere medicine january rule subject ongoing litigation cms preliminarily enjoin implement rule adversely impact legislative regulatory action difficult predict impact use reimbursement product product pricing discount rebate united states european union significant potentially significant market product product candidate government authority thirdparty payer increasingly attempt limit regulate price medical product services united states volume drug pricingrelate bill dramatically increase recent year example congress propose bill change medicare benefit impose inflation base rebate list price drug grow fast inflation increase manufacturer contribution benefit phase addition state legislature consider pass law legislation seeks indirectly directly regulate pharmaceutical drug pricing require manufacturer publicly report proprietary pricing information create review board price state agency encourage use generic drug initiative legislation cause add pricing pressure product result impact business uncertain country outside united states include european union member state establish complex lengthy procedure obtain price approval coverage reimbursement periodically review pricing reimbursement decision outcome review predict adverse effect pricing reimbursement medicinal product european union member states reduction price medicinal product member state affect price member state negative impact financial result substantial portion product sale subject significant discount list price include rebate require pay state medicaid agency discount provide b cover entity change b program medicaid program federal state level material adverse effect business example december cms issue final rule certain change calculation rebate medicaid drug rebate program change effective january final rule change requirement exclude manufacturer copay coupon medicaid good price change effect substantially increase medicaid rebate obligation decrease price charge b cover entity continue growth b program limit price charge increase number customer addition standard reimbursement structure adequately reimburse innovative therapy example begin fiscal year cms establish new severity adjust diagnosis relate group drg medicare inpatient reimbursement car product yescarta tecartus new drg significantly high base payment prior drg payment available sufficient reimburse hospital cost care patient receive yescarta tecartus reimbursement align account treatment cost medicare beneficiary deny access misalignment impact willingness hospital offer therapy doctor recommend therapy additionally european union barrier reimbursement individual country limit uptake yescarta tecartus addition estimate rebate require pay connection sale particular quarter base claim datum prior quarter united states actual rebate claim typically payer quarter arrear actual claim payment vary significantly estimate experience adverse impact result import country product available low price import unapprove generic counterfeit version product price product base local market economic competition differ country country sale country relatively high price reduce product import resold country low price market example sale affect fda permit importation drug canada enter agreement generic drug manufacturer license agreement medicine patent pool unite nationsbacke public health organization allow generic drug manufacturer manufacture generic version certain product distribution certain low middleincome country adversely affect generic version product produce andor distribute agreement export united states europe market high price european union require permit product purchase european union member state sell member state purchase product country sell price relatively low resale country sell price relatively high affect inventory level hold wholesaler cause relative sale level country fluctuate quarter quarter reflect actual consumer demand give quarter additionally divert product country approve patient source divert product outside legitimate supply chain divert product handled ship store inappropriately affect efficacy product harm patient adversely impact aware existence buyer club world promote personal importation generic version product approve use country import result patient risk take unapproved medication purport potency claim contain harmful substance adversely impact party illegally distribute sell counterfeit version medicine meet rigorous quality standard manufacturing supply chain counterfeit medicine pose risk patient health safety raise risk product recall action discourage distribution sale counterfeit version medicine world successful adversely affect result product development supply chain risk face risk clinical trial include potential unfavorable result delay anticipate timeline disruption require demonstrate safety efficacy product develop intend use extensive preclinical study clinical trial result preclinical early clinical study accurately predict result later largescale clinical trial successfully complete largescale clinical trial result marketable product product candidate fails achieve primary endpoint clinical trial safety issue arise result clinical trial inadequate support regulatory approval product candidate commercialization product candidate delay halt addition face challenge clinical trial protocol design adversely impact clinical trial product candidate pipeline delay terminate face numerous risk uncertaintie product candidate prevent completion development product candidate risk include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain fda regulatory agency approval result product candidate successfully commercialize strategic decision discontinue development product candidate example believe commercialization difficult relative opportunity pipeline key anticipated milestone product candidate include phase datum readout sacituzumab govitecanhziy treatment hormone receptor positive human epidermal growth factor receptor negative metastatic breast cancer patient axicabtagene ciloleucel treatment second line diffuse large b cell lymphoma adversely impact favorable result study program pipeline complete timely basis addition clinical trial involve commercial product raise new safety issue exist product addition extensively outsource clinical trial activity usually perform small portion startup activity inhouse rely independent thirdparty contract research organization cro perform clinical study include document preparation site identification screen preparation prestudy visit train program management patient enrollment ongoing monitoring site management bioanalytical analysis important aspect service perform cros direct control dispute disruption relationship cro clinical trial delay regulatory submission rely quality validity clinical work perform thirdparty cro cro process methodology result determine invalid inadequate clinical data result relate regulatory approval adversely affect face manufacture difficulty delay interruption include thirdparty manufacturer corporate partner product manufacture facility thirdparty manufacturer corporate partner result complex highly regulate manufacturing process depend thirdparty manufacturer corporate partner perform manufacturing activity effectively timely basis majority active pharmaceutical ingredient drug product party independent entity subject unique operational financial risk control thirdparty manufacturer corporate partner subject good manufacturing practice gmp extensive regulation govern manufacturing process stability testing record keep quality standard define fda european medicine agency ema comparable regulation jurisdiction manufacture operation subject routine inspection regulatory agency adverse development affect result manufacturing operation operation thirdparty manufacturer corporate partner result shipment delay inventory shortage lot failure product withdrawal recall interruption commercial supply product need inventory writeoff incur charge expense product fail meet specification quality standard undertake costly remediation effort seek costly manufacturing alternative development increase manufacturing cost cause lose revenue market share damage reputation addition manufacturing issue cause delay clinical trial application regulatory approval example unable remedy deficiency cite fda regulatory agency inspection currently market product time regulatory approval product candidate development adversely affect risk regulatory agency country marketing application pende undertake similar additional review apply heighten standard review delay regulatory approval product country business adversely affect approval product candidate delay production product interrupt able obtain material supply necessary conduct clinical trial manufacture sell product limit ability generate revenue need access certain supply product conduct clinical trial manufacture sell product unable purchase sufficient quantity material find suitable alternative material timely manner development effort product candidate delay ability manufacture product limited supplier key component material name new drug application marketing authorization application file regulatory authority product candidate seek marketing approval significant delay occur qualification new supplier require manufacturer qualified regulatory authority manufacturer continue expend time money effort area production quality control maintain compliance gmp manufacturer subject regular periodic inspection regulatory authority follow initial approval result inspection regulatory authority determine equipment facility laboratory process comply applicable regulation condition product approval regulatory authority suspend manufacturing operation manufacture operation single supplier product suspend unable generate sufficient quantity commercial clinical supply product meet market demand addition delivery material supplier interrupt reason unable ship certain product commercial supply supply product candidate development clinical trial product material utilize operation manufacture facility able replace timely manner commercially reasonable term problem single supplier depend include event disaster earthquake equipment failure difficulty negatively impact development commercialization effort significant portion raw material intermediate manufacture antiviral product supply thirdparty manufacturer corporate partner outside united states result political economic factor specific country region include change interpretation trade regulation compliance requirement tax legislation limit prevent party outside united states supply material adversely affect ability manufacture supply antiviral product meet market need material adverse effect operating result encounter difficulty ability conduct clinical trial product candidate manufacture sell product impair regulatory legal risk operation depend compliance complex fda comparable international regulation failure obtain broad approval timely basis maintain compliance delay halt commercialization product product develop approve marketing sale regulatory authority approve subject extensive regulation fda ema comparable regulatory agency country file anticipate file marketing approval additional country additional indication product year future marketing application file approve regulatory authority timely basis marketing approval grant product significant limitation use state certainty product candidate development approve launch able develop license acquire additional product candidate product product launch commercially successful manufacture sell product subject extensive regulation review example fda rule require conduct postapproval clinical study assess know risk signal risk identify unexpected risk certain circumstance required implement risk evaluation mitigation strategy program product include medication guide patient package insert communication plan healthcare provider restriction distribution use product element fda deem necessary assure safe use drug discovery previously unknown problem market product product candidate include safety resistance drug interaction issue problem manufacture safety report promotional activity result regulatory approval delay deny grant significant restriction product include limitation withdrawal product market failure comply requirement impose fda result significant civil monetary penalty fine suspension regulatory approval product recall seizure product criminal prosecution impact evolve law regulation legislative regulatory action applicable health care industry health care industry subject federal state international law regulation pertain drug reimbursement rebate price report health care fraud abuse datum privacy security united states law include antikickback false claim law law regulation relate medicare medicaid programs federal state program medicaid rebate statute individual state law relate pricing sale marketing practice health insurance portability accountability act federal state law relate privacy security health information actual allege violation law relate regulation punishable criminal andor civil sanction include instance substantial fine civil monetary penalty exclusion participation federal state health care program include medicare medicaid department veterans affairs department defense health program action executive oversee business significant remediation measure negative publicity consequence law regulation broad scope subject change evolving interpretation require incur substantial cost associate compliance alter sale marketing practice example united states challenge affordable care act aca currently pende supreme court result uncertainty acas future viability destabilization health insurance market result impact business uncertain material addition government price report payment regulation complex continually assess method calculate report pricing accordance obligation methodology calculation inherently subjective subject review challenge government agency disagree interpretation government disagree report calculation need restate previously report datum subject additional financial legal liability continue enhance scrutiny companysponsore patient assistance program include copay assistance program manufacturer donation thirdparty charity provide assistance enhance scrutiny government reimbursement support offering clinical education program promotional speaker program agent vendor deem fail comply law regulation government guidance area subject criminal civil sanction similar violation competitor negatively impact industry reputation increase scrutiny business product description government investigation relate litigation note commitment contingency note consolidated financial statement include ii item annual report subject risk significant safety issue arise market product product candidate additional study conduct subsequent obtaining marketing approval product product long period time patient include patient underlie health problem patient take medicine expect continue find new issue relate safety resistance drug interaction issue require change product label additional warning contraindication narrow indication halt sale product regulatory authority move active transparent pharmacovigilance make great amount standalone safety information clinical trial datum directly available public website mean periodic safety update report summarie risk management plan summarie adverse event datum safety information appropriate context expertise misinterpret lead misperception legal action success depend significant degree ability obtain defend patent intellectual property right domestically internationally operate infringe patent proprietary right party patent proprietary right important business business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology success depend significant degree ability obtain patent license patent right preserve trade secret internal knowhow defend infringement patent effort invalidate operate infringe intellectual property patent application confidential period time patent issue know competitor file patent application technology cover pende application invent file application direct technology subject patent application competitor file patent application cover technology participate litigation postgrant proceeding patent trademark office proceeding determine right patent validity patent grant litigation proceeding unpredictable expensive divert management attention operation ultimately successful adversely impact generic manufacturer seek continue seek fda approval market generic version product abbreviate new drug application anda application process typically manufacturer seek approval generic drug description anda litigation commitment contingency note consolidated financial statement include ii item annual report entry generic version product future lead market share price erosion find infringe valid patent party require pay significant monetary damage prevent commercialize product require obtain license party able obtain alternative technology require license commercially reasonable term fail obtain license alternative technology unable develop commercialize product aware patent patent application own party party claim cover use sofosbuvir axicabtagene ciloleucel bictegravir example february viiv file lawsuit district court delaware allege commercialization bictegravir sell commercially combination taf ftc biktarvy infringe viiv patent patent covering viivs dolutegravir bictegravir structurally different dolutegravir believe bictegravir infringe claim patent court set trial date january lawsuit viiv seek billion dollar allege damage comprise viivs lose profit royalty sale bictegravir launch trial addition court find liable infringement expect viiv seek royalty sale trial viiv calculate damage base cumulative revenue biktarvy launch total billion december predict certainty ultimate outcome litigation adverse judgment result substantial monetary damage include viivs lose profit royalty trial goingforward royalty stream future sale description litigation relate matter note commitment contingency note consolidated financial statement include ii item annual report furthermore rely unpatented trade secret improvement unpatente internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor certain party comply confidentiality agreement adequate remedy breach trade secret internal knowhow technological innovation know independently discover competitor rd agreement invention jointly own corporate partner case exclusive property party certain circumstance difficult determine own particular invention dispute arise invention adversely affect trade secret internal know technological innovation confidential information know independently discover competitor enter dispute ownership invention face potentially significant liability increase expense litigation government investigation relate product operation involve number litigation investigation disputerelate matter require expend substantial internal financial resource include ongoing litigation relate yescarta biktarvy product ongoing product liability litigation relate tdf product matter require pay significant monetary damage include royalty payment past future sale expect matter continue require high level internal financial resource foreseeable future matter reduce expect continue reduce earning require significant management attention addition testing manufacturing marketing use commercial product product candidate development involve substantial risk product liability claim claim directly consumer healthcare provider pharmaceutical company limited insurance product liability arise claim exceed coverage description litigation investigation disputerelate matter note commitment contingency note consolidated financial statement include ii item annual report outcome legal proceeding legal proceeding bring investigation investigation initiate disputerelate matter inherently uncertain adverse development outcome result significant expense monetary damage penalty injunctive relief operational risk business future adversely affect outbreak epidemic pandemic contagious disease include recent covid outbreak actual threaten outbreak epidemic pandemic contagious disease covid significantly disrupt global operation adversely affect business financial condition result operation example covid pandemic cause significant volatility uncertainty international market result increase risk operation addition development discuss ii item management discussion analysis financial condition result operation monitor number risk relate pandemic include follow supply chain pandemic result disruption supply chain distribution future example quarantine shelterinplace governmental order policy travel restriction airline capacity route reduction safety guideline health impact pandemic impact availability productivity product personnel manufacturer distributor freight carrier necessary component supply chain addition unfavorable change availability cost raw material intermediate material necessary production result high cost disruption supply chain interruption distribution capability clinical trial pandemic adversely affect continue adversely affect certain clinical trial include ability initiate complete clinical trial anticipated timeline ongoing trial clinical trial site impose restriction patient visit limit risk possible covid exposure experience issue participant compliance clinical trial protocol result quarantine travel restriction interruption healthcare service risk closure clinical site necessary pandemic relate guidance restriction continue evolve forego reason experience delay new subject enrollment clinical trial continue experience overall delay clinical trial risk biased data collection certain clinical trial site remain open result challenge anticipate filing marketing timeline certain product adversely impact regulatory review operation fda ema regulatory agency adversely affect experience delay necessary interaction regulatory authority world include respect anticipate filing factor result pandemic adversely impact ability launch new commercial product patient access pandemic limited patient ability willingness access seek care healthcare provider initiate new therapy result low demand product particularly respect hiv prevention hepatitis c virus hcv treatment example see reduction prescription refill hiv prevention result high discontinuation addition rise unemployment experience shift payer mix governmentfunde coverage uninsured segment employee face risk relate health safety morale productivity employee include safe occupancy site pandemic currently gilead site require flexible location employee work home physical location dependent worker mixed location worker continue work gilead site job site enhancement risk protocol include health screening covid testing guarantee maintain continued safe occupancy site onsite employee test positive covid lead mandatory quarantine potential site shutdown office location manufacture plant financial pandemic continue adverse financial impact shortterm potentially result reduce patient access shift payer mix hcv treatment hiv business adversely impact example product sale exclude veklury fourth quarter year decrease respectively compare period continue effect pandemic hcv hiv franchise continue experience fluctuate revenue business infection rate rise fall shelter place restriction periodically tighten ease experience continue experience volatility shortterm revenue fluctuation inventory channel purchase pandemic additional unexpected expense relate pandemic negatively affect result operation factor overall uncertainty disruption cause pandemic result increase volatility decrease predictability result operation volatility stock price pandemic amplify risk describe risk factor section annual report extent pandemic impact business result depend future development uncertain predict confidence include potential future wave pandemic new variant virus impact severity duration pandemic development distribution effectiveness public acceptance vaccine ongoing future action take contain pandemic face risk associate global operation global operation accompany certain financial political economic risk include list foreign currency exchange year end december approximately product sale outside united states significant percentage product sale denominate foreign currency primarily euro face exposure adverse movement foreign currency exchange rate overall net receiver foreign currency benefit weak dollar adversely affect strong dollar hedging program eliminate exposure currency fluctuation adversely impact dollar appreciate significantly certain currency hedge program sufficiently offset effect appreciation antibribery subject foreign corrupt practice act similar worldwide antibribery law govern international operation respect payment government official international operation heavily regulate require significant interaction foreign official operate part world experience governmental corruption degree certain circumstance strict compliance antibribery law conflict local custom practice require interact doctor hospital state control manner different local custom possible certain practice challenge law addition internal control policy procedure protect reckless criminal act commit employee agent enforcement activity antibribery law subject administrative legal proceeding action result civil criminal sanction include monetary penalty exclusion healthcare program risk inherent conduct global business include restrictive government action intellectual property foreign asset nationalization expropriation imposition compulsory license protective economic policy take foreign government trade protection measure import export licensing requirement result imposition trade sanction similar restriction united states government business interruption stem natural manmade disaster climate change earthquake hurricane flooding fire actual threaten public health emergency effort take party prevent mitigate disaster public safety power shutoff facility shutdown uninsured inadequately insure example corporate headquarters foster city certain rd manufacturing facility locate california seismically active region event major earthquake carry adequate earthquake insurance significant recovery time require resume operation political instability disruption geographic region operate regardless cause include war terrorism social unrest political change example january united kingdom withdraw european union initiate transition period united kingdom european union negotiate future relationship uncertainty concern change law regulation govern conduct clinical trial market medicinal product united kingdom follow countrys exit european union uncertainty lead significant complexity risk company ability research develop market medicinal product european union united kingdom depend relationship party sale marketing performance technology development logistic commercialization product failure maintain relationship poor performance company dispute party negatively impact business rely number collaborative relationship party sale marketing performance certain territory example collaboration arrangement janssen sciences ireland uc odefsey compleraeviplera symtuza country rely international distributor sale certain product relationship involve clinical development product partner reliance collaborative relationship pose number risk include risk unable control resource corporate partner devote program product dispute arise respect ownership right technology develop corporate partner disagreement corporate partner cause delay termination research development commercialization product candidate result litigation arbitration contract corporate partner fail provide significant protection fail effectively enforce partner fails perform corporate partner considerable discretion elect pursue development additional product pursue alternative technology product collaboration competitor corporate partner marketing right choose pursue compete technology devote few resource marketing product product development distributor corporate partner unable pay give risk great deal uncertainty success current future collaborative effort effort fail product development commercialization new product delay revenue product decline specialized technical nature business failure attract develop retain highly qualified personnel adversely impact future success depend large continue ability attract develop retain highly qualified scientific technical management personnel personnel expertise clinical testing governmental regulation commercialization ability depend maintain strong workplace culture attractive employee addition competition qualified personnel biopharmaceutical field intense limited pool qualified potential employee recruit face competition personnel company university public private research institution government entity organization additionally change immigration work authorization law regulation difficult employee work transfer jurisdiction operate dependent information technology system infrastructure datum subject cyberattack security breach legal claim dependent information technology system infrastructure datum include kite konnect platform critical maintain chain identity chain custody yescarta multitude complexity computer system inherently vulnerable service interruption destruction malicious intrusion random attack likewise datum privacy security breach employee pose risk sensitive datum include intellectual property trade secret personal information employee patient customer business partner expose unauthorized person public cyberattack increase frequency sophistication intensity include pandemic cyberattack include example deployment harmful malware denialofservice social engineering mean affect service reliability threaten datum confidentiality integrity availability business technology partner face similar risk security breach system adversely affect security posture assurance effort effort partner vendor invest protection information technology infrastructure datum prevent future service interruption identify breach system interruption breach cause loss critical sensitive information include personal information addition insurance sufficient type cover loss result interruption breach system regulator globally impose new datum privacy security requirement include new great monetary fine privacy violation example general datum protection regulation gdpr effective europe establish regulation handle personal datum non compliance gdpr result monetary penalty percent worldwide revenue addition new domestic datum privacy security law california consumer privacy act ccpa effective january passed similarly introduce requirement respect personal information noncompliance ccpa result liability private action subject statutorily define damage event certain datum breach enforcement gdpr ccpa change new law regulation associate enhance protection personal information include case healthcare datum personal information greatly increase cost provide product service prevent offer certain service jurisdiction operate strategic financial risk subject risk associate engage business acquisition licensing arrangement collaboration option equity investment asset divestiture strategic transaction engage future engage transaction business strategy identify suitable transaction future complete transaction timely manner costeffective basis realize expect benefit successful make acquisition closing licensing arrangement collaboration product intellectual property technology acquire license successful require significantly great resource investment anticipate annual impairment testing goodwill indefinitelive intangible asset fourth quarter early impairment indicator exist require generally accept accounting principle need recognize impairment charge product intellectual property technology acquire license successful option structure deal assurance elect exercise option right possible disagreement uncertainty circumstance arise include respect option right appropriately trigger hinder ability realize expect benefit equity investment strategic transaction connection collaboration galapagos nv value equity investment fluctuate decline value successful execution implementation transaction financial condition cash flow result operation adversely affect stock price decline pay substantial amount cash incur additional debt finance strategic transaction additional indebtedness low cash balance result downgrade credit rating limit ability borrow additional fund refinance exist debt favorable term increase vulnerability adverse economic industry condition reduce financial flexibility continue capital investment stock repurchase dividend payment example result cash debt issue connection acquisition immunomedic sp downgrade credit rating adversely impact failure overcome additional risk change effective income tax rate reduce earning subject income taxis tax return audits united states foreign jurisdiction include ireland economic political condition country actively consider change exist tax law predict form timing change differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction adversely affect resolution exposure report period addition significant judgment require determine worldwide provision income taxis factor favorable unfavorable effect income tax rate include limited portion nondeductible annual brand prescription drug fee accounting stock option sharebase award mergersacquisition restructuring ability maintain manufacture operational activity irish facility change mix earning tax jurisdiction operate change overall level pretax earning resolution federal state foreign income tax audits impact income tax provision result mention factor significant item b unresolved staff comment applicable item property corporate headquarters locate foster city california house administrative certain rd activity rd facility emeryville oceanside santa monica california gaithersburg maryland seattle washington morris plain new jersey edmonton canada dublin ireland principal manufacturing facility el segundo la verne oceanside san dimas california morris plain new jersey edmonton canada cork ireland hoofddorp netherland information manufacture facility item business manufacture facility global operation include office europe north america asia south america africa australia middle east believe exist property include own lease site good condition suitable conduct business believe capital resource sufficient purchase lease construct additional facility require meet expect longterm growth need item legal proceeding description significant pende legal proceeding note commitment contingency legal proceeding note consolidated financial statement include ii item annual report item safety disclosure applicable ii item market registrant common equity relate stockholder matter issuer purchase equity security common stock trade nasdaq global select market symbol gild february approximately stockholders record common stock performance graph follow graph compare cumulative total stockholder return past year index standard poor stock index sp index nasdaq biotechnology index nbi index stockholder return show graph necessarily indicative future performance endorse prediction future stockholder return comparison cumulative total return investment past year section soliciting material deem file sec incorporate reference filing securities act exchange act date hereof irrespective general incorporation language filing show cumulative return investment assume investment common stock nbi index sp index december assume dividend reinveste equity compensation plan information follow table provide certain information respect equity compensation plan effect december number common share remain available future number common share weightedaverage issuance equity issue exercise exercise price compensation plan outstanding option warrant outstanding option exclude security million share amount right warrant right reflect column plan category b c equity compensation plan approve security holder equity incentive plan employee stock purchase plan total equity compensation plan approve security holder equity compensation plan approve security holder total account million restrict stock unit performance share award unit phantom share exercise price grant equity incentive plan include award share previously issuable immunomedics inc amend restate longterm incentive plan immunomedic plan assume connection acquisition immunomedics inc subsequently merge equity incentive plan employee stock purchase plan participant permit purchase common stock discount certain date payroll deduction predetermine purchase period accordingly number determinable include award share issuable seven inc equity incentive plan assume connection acquisition seven inc seven subsequently amend restate equity incentive plan material feature gilead sciences inc equity incentive plan seven inc equity incentive plan originally establish seven june connection gilead acquisition seven april gilead assume seven inc equity incentive plan amend restate gilead sciences inc equity incentive plan plan plan intend help company secure retain service eligible award recipient provide incentive person exert maximum effort success company affiliate provide mean eligible recipient benefit increase value gilead common stock april employee consultant seven immediately prior date employee consultant gilead hire follow date eligible receive grant new award plan plan provide award incentive stock option nonstatutory stock option generally exercise price equal fair market value common stock date grant stock appreciation right restrict stock award restrict stock unit award performance stock award stock award performance cash award april aggregate number share common stock issuable plan date april gilead grant restrict stock unit stock option plan type equity award outstanding plan december million share gilead common stock remain available issuance plan issuer purchase equity security quarter board director authorize billion stock repurchase program program repurchase open market privately negotiate transaction repurchase program start april quarter board director authorize new billion stock repurchase program program commence completion program purchase program open market privately negotiate transaction repurchase retire million share common stock billion open market transaction program december remain authorize repurchase program billion table summarize stock repurchase activity month end december maximum fair total number value share total number average share purchase share price pay publicly purchase purchase share announce program program thousand dollar thousand million october october november november december december total total thousand share transfer employee satisfaction minimum tax withholding obligation associate vest restricted stock unit period purchase share common stock open market pursuant repurchase program item select financial datum gilead sciences inc select consolidated financial datum year end december millions share amount consolidated statement income datum total revenue total cost expense income operation income tax expense benefit net income net income attributable gilead net income share attributable gilead common stockholder basic share share calculation basic net income share attributable gilead common stockholder dilute share share calculation dilute cash dividend declare share december millions consolidated balance sheet datum cash cash equivalent marketable debt security work capital total asset longterm obligation longterm debt include current portion retain earning total stockholder equity management discussion analysis financial condition result operation include item annual report description result operation record acquire inprocess research development iprd expense billion primarily relate acquisition seven inc seven collaboration investment enter year record acquire iprd expense billion primarily billion upfront collaboration licensing expense relate global research development collaboration galapagos nv pretax impairment charge million asset obtain acquisition kite pharma inc kite record discrete tax benefit million relate settlement tax authority record defer tax benefit billion relate intangible asset transfer foreign subsidiary ireland united states record defer tax charge million relate transfer acquire intangible asset foreign subsidiary united states december record estimate billion net charge relate enactment tax cut job act tax reform tax reform lower corporate tax rate united states effective tax year begin december connection acquisition immunomedic issue billion principal senior unsecured note borrow aggregate principal billion threeyear term loan facility repay billion principal senior unsecured note maturity repay billion principal senior unsecured note maturity repay billion principal senior unsecured note maturity repay billion term loan borrow connection acquisition kite connection acquisition kite issue billion aggregate principal senior unsecured note borrow billion aggregate principal term loan facility credit agreement billion repay issue billion principal senior unsecured note repay million principal balance convertible senior note million principal balance senior unsecured note maturity note debt credit facility note consolidated financial statement include item annual report additional information cash payment billion primarily relate acquisition immunomedic october seven april note acquisition note consolidated financial statement include item annual report additional information item management discussion analysis financial condition result operation follow management discussion analysis financial condition result operation mda intend help reader understand result operation financial condition mda provide supplement read conjunction audit consolidated financial statement accompany note consolidated financial statement disclosure include annual report include disclosure item risk factor additional information relate comparison result operation year include item management discussion analysis financial condition result operation file securities exchange commission sec incorporate reference annual report consolidate financial statement prepare accordance generally accept accounting principle present dollar management overview gilead sciences inc gilead biopharmaceutical company pursue achieve breakthrough medicine decade goal create healthy world people commit advance innovative medicine prevent treat lifethreatening disease include hiv viral hepatitis cancer operate country worldwide headquarters foster city california portfolio market product include ambisome atripla biktarvy cayston complera descovy descovy prep emtriva epclusa eviplera genvoya harvoni hepsera jyseleca letairis odefsey ranexa sovaldi stribild tecartustm trodelvy truvada truvada prep tybost veklury vemlidy viread vosevi yescarta zydelig approval status jyseleca vary worldwide jyseleca approve united states sell distribute authorize generic version epclusa harvoni united states separate subsidiary asegua therapeutics llc addition sell distribute certain product corporate partner collaborative agreement business highlight financial performance strong despite global impact covid pandemic clear reflection solid underlie fundamental business drive hiv franchise increase demand see veklury amid covid pandemic continue expand strengthen commercial portfolio clinical pipeline therapeutic area drive future growth potential april acquire seven inc seven approximately billion gain investigational drug candidate magrolimab currently phase clinical study number hematological cancer include myelodysplastic syndrome acute myeloid leukemia nonhodgkin lymphoma solid tumor october acquire immunomedics inc immunomedics approximately billion gain trodelvy tropdirecte antibodydrug conjugate grant accelerated approval food drug administration fda treatment adult patient metastatic triplenegative breast cancer mtnbc trodelvy potential broad applicability multiple tumor type study monotherapy combination agent additional tumor type include hrher breast cancer urothelial cancer nonsmall cell lung cancer solid tumor december enter definitive agreement acquire myr gmbh closing subject regulatory clearance condition acquisition provide hepcludex bulevirtide conditionally approve european medicine agency ema treatment chronic hepatitis delta virus hdv july significantly expand oncology portfolio license strategic collaboration equity investment thirdparty collaboration partner additional information include note collaboration arrangement note consolidated financial statement include item annual report addition asset acquire pursuant strategic transaction develop therapy treatment portfolio jyseleca tecartus veklury fdaapprove antiviral therapy covid effort demonstrate continued commitment advance innovative medicine area unmet need key product pipeline corporate update category therapeutic area description regulatory approval viral disease submission fda european commission ec japanese ministry health labour welfare jmhlw grant approval conditional marketing authorization regulatory approval respectively veklury treatment patient covid fda approve supplemental new drug application epclusa treatment child age old weighing kg hepatitis c virus hcv oncology fda ec grant accelerated approval conditional marketing authorization respectively tecartus treatment adult patient relapse refractory mantle cell lymphoma submit supplemental biologic license application sbla fda approval trodelvy treatment adult patient mtnbc base overall efficacy safety result phase ascent trial kite pharma inc kite submit sbla fda yescarta treatment relapse refractory indolent non hodgkin lymphoma kite receive ema approval implement variation yescarta marketing authorization endtoend manufacture fda grant breakthrough therapy designation magrolimab firstinclass investigational monoclonal antibody treatment newly diagnose myelodysplastic syndrome inflammatory disease ema validate review application gilead galapagos nv galapagos new indication approve license filgotinib mg propose indication treatment adult moderately severely active ulcerative colitis jmhlw ec grant regulatory approval marketing authorization jyseleca respectively treatment adult moderate severe active rheumatoid arthritis corporate development viral disease gilead vir biotechnology inc establish clinical collaboration relate hepatitis b virus january gilead gritstone oncology inc announce company enter collaboration option license agreement relate curative treatment hiv february veklury distribution begin october start distribute veklury united states conclusion previous distribution agreement federal government gilead european union sign joint procurement agreement cover purchase veklury sixmonth period april option extend party additional sixmonth period board appointments jeffrey bluestone phd president chief executive officer ceo sonoma biotherapeutic sandra j horn retire chief medical officer global head product development roche javier j rodriguez ceo davita inc anthony welters retire senior advisor office ceo unitedhealth group inc community support february announce new partnership wake forest university school divinity ongoing compass initiative help mitigate hiv epidemic southern united states launch racial equity community impact fund initially provide million grant organization work community advocacy mobilization social justice educational innovation covid donate million individual dose remdesivir free charge donation support current nonprofit grantee global gilead covid acute relief emergency support grantee fund donation san mateo strong fund mayor fund los angeles announced discuss update detail press release available website httpswwwgileadcomnewsandpresspressroompressrelease additional information find disclosure file furnish sec include current report form k quarterly report form q applicable reader encourage review press release available website mention financial highlight million percentage share amount change change total revenue net income attributable gilead diluted earning share compare total revenue increase billion compare billion primarily veklury sale high product sale hiv product include continue patient uptake biktarvy growth descovy preexposure prophylaxis prep increase partially offset low sale volume truvada emtricitabine ftc tenofovir disoproxil fumarate tdfbase product primarily loss exclusivity truvada atripla united states october low sale hcv product impact covid pandemic expect decline sale letairis ranexa generic entry half net income attributable gilead million diluted share compare billion diluted share primarily unfavorable change fair value equity investment galapagos billion discrete tax benefit record relate intraentity transfer intangible asset different tax jurisdiction higher acquire inprocess research development iprd expense relate acquisition seven collaboration investment enter year high acquisitionrelate expense strategy outlook purpose deliver lifechange medication patient need scientific breakthrough innovation strong operational execution strategic ambition bring transformative therapy patient ii biotech employer partner choice iii deliver shareholder value sustainable responsible manner strategic priority reflect deliver ambition expand internal external innovation ii strengthen portfolio strategy decision make iii increase patient benefit access iv continue evolve culture continue focus execute strategy expand strengthen commercial portfolio clinical pipeline new therapeutic area include oncology inflammation maintain leadership antiviral medication continue growth biktarvy development lenacapavir expansion viral hepatitis business ongoing effort develop safe effective antiviral patient suffer viral infection expand product pipeline continue focus employee evolution culture effort promote racial equity covid pandemic continue impact business broad market dynamic expect gradual recovery underlie market dynamic start second quarter truvada atripla sale expect continue decline quarter multiple generic expect enter market start second quarter biktarvy trodelvy vemlidy cell therapy expect key growth driver absorb year impact loss exclusivity truvada atripla united states veklury sale generate highly dynamic complex global environment continue evolve result veklury sale subject significant volatility uncertainty future product demand depend nature covid pandemic include duration pandemic infection rate hospitalization availability alternative therapie vaccine develop acquisition immunomedic continue contribute revenue growth capital allocation priority remain unchanged plan prioritize investment business rd pipeline maintain rigorous focus discipline expense management ability deliver strategy objective subject number uncertainty include limited effect covid pandemic remain unpredictable continuation uncertain global macroeconomic environment ability realize potential benefit acquisition collaboration license arrangement ability initiate progress complete clinical trial currently anticipate timeframe possibility unfavorable result new ongoing clinical trial additional pricing pressure payer competitor high anticipate effect loss exclusivity truvada atripla slow anticipate growth biktarvy trodelvy vemlidy cell therapy product increase discount chargeback rebate ongoing contract future negotiation commercial government payer market share price erosion cause introduction generic loss exclusivity product inaccuracy hcv patient start estimate potential government action effect lower price largerthan anticipate shift payer mix highly discount payer segment volatility foreign currency exchange rate result operation total revenue follow table summarize periodoverperiod change revenue million percentage change change product sale hiv product hcv product veklury nm nm cell therapy product trodelvy nm nm product total product sale royalty contract revenue total revenue nm meaningful compare total product sale total product sale increase billion compare billion primarily veklury sale high product sale hiv product include continue patient uptake biktarvy growth descovy prep increase partially offset low sale volume truvada ftctdfbase product primarily loss exclusivity truvada atripla united states october lower hcv sale lower patient start covid pandemic expect decline sale letairis ranexa generic entry half hiv product sale hiv product sale increase billion compare billion primarily continue patient uptake biktarvy growth descovy prep partially offset low sale volume truvada ftctdfbase product drive loss exclusivity truvada atripla united states october low average net selling price drive unfavorable payer mix primarily high public health service utilization hiv franchise include prep unfavorably impact covid pandemic hiv product sale include favorable net adjustment primarily government rebate discount descovy ftctafbase product sale increase major market compare increase united states primarily continue patient uptake biktarvy growth descovy prep partially offset low sale volume genvoya increase europe international location primarily high sale volume biktarvy partially offset low sale volume genvoya truvada ftctdfbase product sale decrease united states europe compare decrease united states primarily low sale volume drive loss exclusivity truvada atripla october patient switch regimen contain ftctaf expect truvada sale continue decline multiple generic expect enter market start second quarter decrease european sale primarily low sale volume result broad availability generic version truvada patient switch regimen contain ftctaf hcv product sale hcv product sale decrease billion compare billion primarily low sale volume drive low patient start united states europe attributable covid pandemic continue decline total market patient start unrelated pandemic low average net selling price reflect high sale return provision discount hcv product sale include favorable net adjustment primarily government rebate discount decrease hcv product sale united states europe compare primarily lower patient start include decline attributable decrease health care provider visit screening covid pandemic low average net selling price decrease europe impact favorable net adjustment primarily government rebate discount reoccur decrease hcv product sale international location compare primarily low sale volume veklury veklury generate billion sale primarily united states europe reflect high hospitalization treatment rate fourth quarter covid surge cell therapy product sale cell therapy product sale include yescarta tecartus increase million compare million primarily continued uptake yescarta europe quarter product launch tecartus united states trodelvy trodelvy generate million sale united states follow acquisition immunomedics october product sale product sale include vemlidy viread letairis ranexa zydelig ambisome cayston jyseleca decrease billion compare billion primarily expect decline sale letairis ranexa generic entry half partially offset high sale volume vemlidy international location grosstonet deduction record product sale net estimate government rebate chargeback cash discount prompt payment distributor fee sale return provision relate cost deduction product sale generally refer grosstonet gtn deduction total billion gross product sale compare billion gross product sale billion billion gross product sale relate government rebate chargeback billion relate cash discount prompt payment distributor fee relate cost million relate sale return provision product sale geographic area total product sale generate outside united states respectively face exposure movement foreign currency exchange rate primarily euro foreign currency exchange contract hedge percentage foreign currency exposure foreign currency exchange net hedge unfavorable impact product sale million base comparison foreign currency exchange rate product sale united states increase billion compare billion primarily sale veklury continue patient uptake biktarvy growth descovy prep partially offset decrease sale truvada ftctdfbase product drive loss exclusivity truvada atripla united states october increase partially offset low sale volume letairis ranexa low sale hcv product decrease sale hcv product primarily lower patient start average net selling price discuss product sale europe increase billion compare billion primarily sale veklury continue patient uptake biktarvy yescarta increase partially offset low patient start average net selling price discuss product sale europe include favorable net adjustment primarily government rebate discount product sale international location increase billion compare billion primarily high sale volume biktarvy veklury vemlidy follow table summarize periodoverperiod change product sale million percentage change change hiv product descovy ftctaf base product biktarvy nm biktarvy europe nm biktarvy international nm nm nm descovy descovy europe descovy international nm genvoya genvoya europe genvoya international odefsey odefsey europe odefsey international revenue share symtuza nm revenue share symtuza europe nm revenue share symtuza international nm nm nm total descovy ftctaf base product total descovy ftctaf base products europe total descovy ftctaf base product international nm truvada ftctdf base product atripla atripla europe atripla international complera eviplera complera eviplera europe complera eviplera international stribild stribild europe stribild international truvada truvada europe truvada international total truvada ftctdf base product total truvada ftctdf base products europe total truvada ftctdf base product international hiv hiv europe hiv international nm total hiv total hiv europe total hiv international hcv product ledipasvir sofosbuvir ledipasvir sofosbuvir europe ledipasvir sofosbuvir international sofosbuvir velpatasvir sofosbuvir velpatasvir europe sofosbuvir velpatasvir international hcv hcv europe hcv international total hcv total hcv europe total hcv international veklury veklury nm nm veklury europe nm nm veklury international nm nm nm nm cell therapy product yescarta yescarta europe nm nm yescarta international nm nm tecartus nm nm tecartus europe nm nm tecartus international nm nm nm nm total cell therapy total cell therapy europe nm nm total cell therapy international nm nm trodelvy nm nm product ambisome ambisome europe ambisome international letairis ranexa vemlidy vemlidy europe vemlidy international nm viread viread europe viread international zydelig zydelig europe zydelig international europe international total total europe total international total product sale total product sale europe total product sale international nm meaningful represent revenue cobicistat c emtricitabine ftc tenofovir alafenamide taf symtuza darunavircftctaf fix dose combination product commercialize janssen sciences ireland unlimited company include emtriva tybost amount consist sale harvoni authorize generic version harvoni sell separate subsidiary asegua therapeutics llc amount consist sale epclusa authorize generic version epclusa sell separate subsidiary asegua therapeutics llc include vosevi sovaldi include cayston hepsera jyseleca cost expense follow table summarize periodoverperiod change cost expense million percentage change change cost good sell product gross margin bps bps research development rd expense acquire iprd expense nm sell general administrative sga expense nm meaningful cost good sell product gross margin cost good sell decrease million compare primarily inventory writedown charge million million relate slow move excess raw material work process inventory primarily low longterm demand hcv product decrease cost good sell partially offset high manufacturing rampup expense relate veklury treatment covid acquisitionrelated expense amortization finitelive intangible asset inventory stepup charge accelerate stockbased compensation expense relate acquisition immunomedic addition royalty expense decrease million compare primarily low sale product contain elvitegravir letairis atripla product gross margin increase compare primarily factor describe research development expense rd expense consist primarily clinical study perform contract research organization material supply payment collaborative arrangement include milestone payment license fee expense reimbursement collaboration partner personnel cost include salary benefit stockbase compensation expense overhead allocation consist support infrastructure cost track total rd expense product candidate therapeutic area development phase manage rd expense identify rd activity anticipate perform give period prioritize effort base scientific datum probability technical regulatory successful development market potential available human capital resource consideration continually review rd project base unmet medical need necessary reallocate resource internal rd portfolio external opportunity believe good support longterm growth business follow table provide breakout rd expense major cost type million percentage change change clinical study outside service personnel infrastructure expense stockbase compensation expense total rd expense increase billion compare primarily high clinical trial expense relate investigation remdesivir treatment covid include material cost fourth quarter charge million million connection agreement amend exist arrangement galapago commercialization development jyseleca accelerate stockbased compensation expense million relate acquisition immunomedic seven high investment oncology program include magrolimab investigational anticd monoclonal antibody less extent trodelvy accrual milestone payment million pionyr immunotherapeutic inc pionyr increase partially offset low clinical trial expense completion certain inflammation program low cost result pause postponement certain clinical trial covid pandemic acquire inprocess research development expense acquire iprd expense reflect iprd impairment initial cost externally develop iprd project acquire directly transaction business combination alternative future use include upfront payment relate collaboration initial cost right iprd project begin second quarter acquire iprd expense report separately research development expense consolidate statement income iprd asset capitalize tested impairment fourth quarter year early impairment indicator exist iprd impairment charge record acquire iprd expense billion primarily relate acquisition seven collaboration investment enter year arcus biosciences inc pionyr tango therapeutics inc tizona therapeutics inc jounce therapeutics inc acquire iprd expense billion include billion upfront charge relate global research development collaboration agreement galapago million impairment charge asset obtain kite acquisition sell general administrative expense sga expense relate sale marketing finance human resource legal administrative activity include information technology investment expense consist primarily personnel cost facility overhead cost outside marketing advertising legal expense general administrative cost sga expense include brand prescription drug bpd fee united states pharmaceutical manufacturer brand drug product require pay portion bpd fee estimate base select government sale prior year percentage total industry government sale truedup receipt invoice internal revenue service sga expense increase million compare primarily accelerate stockbased compensation expense million relate acquisition immunomedic seven million charge relate previously disclose legal settlement increase corporate grant cost associate commercialization effort veklury less extent trodelvy high marketing expense relate biktarvy donation remdesivir increase partially offset low travel spend covid pandemic bpd fee expense million million million respectively bpd fee expense taxdeductible income expense net interest expense follow table summarize periodoverperiod change income expense net interest expense million percentage change change income expense net nm nm interest expense nm meaningful unrealized loss primarily relate investment galapago unfavorably impact income expense net compare unrealized gain income taxis follow table summarize periodoverperiod change income tax expense benefit million percentage income income taxis income tax expense benefit effective tax rate effective tax rate increase compare primarily billion acquire iprd charge record connection acquisition seven million certain acquire iprd charge billion unfavorable change fair value equity investment galapagos nondeductible tax purpose effective tax rate include billion discrete tax benefit relate intraentity intangible asset transfer different tax jurisdiction liquidity capital resource follow table summarize cash cash equivalent marketable debt security working capital december million cash cash equivalent marketable debt security work capital cash cash equivalent marketable debt security cash cash equivalent marketable debt security december decrease billion compare december generate billion operate cash flow utilize billion acquisition include iprd net cash acquire issue senior unsecured note aggregate principal billion net issuance cost borrow aggregate principal billion threeyear term loan facility repay billion principal debt pay cash dividend billion utilize billion repurchase common stock january repay billion senior unsecured note prior april maturity choose repay certain longterm debt obligation prior maturity date base assessment current longterm liquidity capital requirement acquisition myr gmbh expect close quarter agreement consideration payment approximately billion cash approximately billion close work capital work capital current asset current liability decrease billion compare december primarily utilization significant cash cash equivalent marketable debt security acquisition immunomedic seven note reclassification senior unsecured note longterm debt net decrease partially offset increase account receivables veklury sale reclassification portion galapagos equity investment longterm asset account receivable increase billion compare december primarily reflect increase sale drive veklury covid surge fourth quarter accrue liability increase billion compare december primarily reclassification longterm income taxis payable certain tax payment expect year cash flow follow table summarize cash flow activity million net cash provide operating activity invest activity financing activity operate activity cash provide operating activity represent cash receipt disbursement related activity invest financing activity operate cash flow derive adjust net income noncash item change operate asset liability cash provide operating activity decrease million billion compare decrease primarily result change work capital reflect increase account receivable fourth quarter veklury sale certain tax payment tax authority invest activity cash provide investing activity primarily consist purchase sale maturity marketable debt security capital expenditure acquisition include iprd net cash acquire purchase equity security investment cash investing activity billion compare billion change cash provide investing activity billion payment primarily related acquisition immunomedic seven compare billion payment primarily related collaboration equity investment galapago financing activity change cash provide financing activity compare primarily billion proceed september senior unsecured note offer net issuance cost million borrow threeyear term loan facility net issuance cost october connection acquisition immunomedics debt credit facility summary borrowing financing arrangement include note debt credit facility note consolidated financial statement include item annual report choose repay certain longterm debt obligation prior maturity date base assessment current longterm liquidity capital requirement senior unsecured note offer september connection acquisition immunomedic issue senior unsecured note consist million principal float rate note september million principal float rate note september ii billion principal senior note september million principal senior note october billion principal senior note october billion principal senior note october billion principal senior note october senior unsecured note repayment repay maturity billion billion principal senior unsecured note respectively january repay billion senior unsecured note prior april maturity term loan facility october connection acquisition immunomedic borrow aggregate principal billion threeyear term loan facility term loan facility liability relate future royalty connection acquisition immunomedic assume liability relate funding arrangement originally enter immunomedics rpi finance trust rpi liability relate future royalty primarily include longterm debt net consolidated balance sheet note acquisition note consolidated financial statement include item annual report additional information credit facility june terminate billion revolving credit facility mature revolve credit facility enter new billion revolve credit facility mature june revolve credit facility term substantially similar revolve credit facility revolve credit facility work capital requirement general corporate purpose include limitation acquisition december amount outstanding revolve credit facility require comply certain covenant note indentures december violation covenant capital return program detail stock repurchase program dividend include note stockholder equity note consolidated financial statement include item annual report stock repurchase program quarter board director authorize billion stock repurchase program program repurchase open market privately negotiate transaction start repurchase program april purchase million million share common stock program billion billion respectively quarter board director authorize new billion stock repurchase program program commence completion program purchase program open market privately negotiate transaction december remain authorize repurchase program billion dividend declare pay quarterly cash dividend aggregate billion share common stock billion share common stock respectively february announce board director declare quarterly cash dividend increase share common stock payment date march stockholders record close business march future dividend subject declaration board director capital resource believe exist capital resource supplement cash flow generate operation adequate satisfy capital need foreseeable future future capital requirement depend factor include limited follow commercial performance current future product progress scope rd effort include preclinical study clinical trial cost timing outcome regulatory review expansion sale marketing capability possibility acquire additional manufacturing capability office facility possibility acquire company new product debt service requirement establishment additional collaborative relationship company cost associate defense settlement adverse result government investigation litigation future require additional funding form proceed equity debt financing fund require guarantee available favorable term critical accounting policy estimate judgment discussion analysis financial condition result operation base consolidated financial statement include item annual report prepare accordance generally accept accounting principle preparation financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate believe follow critical accounting policy reflect significant judgment estimate preparation consolidated financial statement revenue recognition recognize revenue product sale control product transfer generally shipment delivery customer certain case correspond sale customer party revenue recognize net estimate government rebate chargeback cash discount prompt payment distributor fee sale return provision relate deduction deduction product sale refer gtn deduction estimate record period relate product sale occur variable consideration include net sale price extent significant reversal cumulative revenue recognize probable occurring uncertainty associate variable consideration subsequently resolve government rebate chargeback represent majority gtn deduction subject complex estimation process require significant judgment management lag date product sale date relate rebate chargeback claim settle government rebate chargeback include amount payable payer healthcare provider program vary product payer individual payer plan qualified program purchase product wholesaler distributor low contractual price wholesaler distributor charge difference acquisition cost low contractual price rebate chargeback estimate primarily base product sale expect payer mix discount rate require significant estimate judgment additionally develop estimate government rebate chargeback consider follow factor historical estimate payer mix statutory discount requirement contractual term historical claim experience processing time lag estimate patient population know market event trend market research channel inventory datum obtain major wholesaler pertinent internal external information assess update estimate quarter reflect actual claim current information actual government rebate chargeback claim prior period varied estimate amount deduct product sale year end december believe methodology use estimate government rebate chargeback reasonable appropriate give current fact circumstance actual result differ significantly estimate government chargeback payable direct customer classify reduction account receivable consolidated balance sheet total million million december respectively note financial information note consolidated financial statement include item annual report additional information government rebate payable party payer healthcare provider generally record accrue government rebate consolidated balance sheet total billion december allowance sale return generally record accrue liability consolidate balance sheet total million million december respectively increase allowance sale return reflect estimate veklury sale return increase hcv hiv sale return provision follow table summarize consolidated activity end balance government rebate chargeback account balance decreaseincrease balance end million begin year product sale payment year year end december activity relate sale activity relate sale prior total year end december activity relate sale activity relate sale prior total acquisition valuation intangible certain judgment determine transaction account acquisition asset business combination determine substantially fair value gross asset acquire transaction concentrate single asset group similar asset transaction treat acquisition asset evaluate input process output associate acquire set activity asset transaction include input substantive process significantly contribute ability create output transaction treat acquisition business account business combination acquisition method accounting require asset acquire liability assume generally record fair value acquisition date excess consideration fair value net asset acquire record goodwill estimate fair value require significant judgment assumption perform impairment testing goodwill annually frequently event change circumstance indicate likely asset impair transaction account acquisition asset goodwill record contingent consideration payment achievement developmental regulatory commercial milestone generally recognize acquisition date asset acquisition upfront payment allocate iprd project acquisition date expense alternative future use addition product development milestone expense achievement valuation intangible asset acquire expect continue acquire intangible asset asset acquisition business combination consolidation variable interest entity identifiable intangible asset measure respective fair value acquisition date intangible asset acquire business combination subject potential adjustment measurement period year acquisition date fair value intangible asset generally determine probabilityweighte income approach discount expect future cash flow present value estimate net cash flow discount discount rate base estimate weightedaverage cost capital company profile similar profile represent rate market participant use value intangible asset discount cash flow model value intangible asset require use significant estimate assumption include limited identification product candidate sufficient substance require separate recognition estimate project future cash flow include revenue operate profit relate product product candidate probability technical regulatory success unapproved product candidate consider stage development time resource need complete development approval product candidate appropriate discount rate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain fda regulatory approval risk relate viability potential alternative treatment future target market believe fair value record intangible asset acquire base reasonable estimate assumption give fact circumstance relate valuation date impairment amortization intangible asset intangible asset relate iprd project acquire business combination capitalize indefinitelive intangible asset completion abandonment associate rd effort period asset consider indefinitelive amortize development complete generally occur regulatory approval market product obtain associate asset deemed finitelive amortize base respective estimate useful life point time primarily straightline basis indefinitelive intangible asset test impairment annually frequently event change circumstance indicate likely asset impair estimate fair value result complex series judgment future event uncertainty assumption point time acquisition date subsequent impairment assessment date change estimate assumption include time product launch pricing reduction failure obtain anticipate regulatory approval deterioration global financial market unanticipate event circumstance decrease project cash flow increase discount rate potentially result impairment charge eventual realize value acquire iprd project vary fair value date acquisition carry value intangible asset exceed estimate fair value impairment charge record write intangible asset estimate fair value example recognize million impairment charge relate iprd project primarily treatment indolent nonhodgkin lymphoma change estimate market opportunity high rate failure inherent discovery development new product example conclude kite program acquire connection acquisition kite justify effort base totality clinical datum gather discontinue program result carry value iprd relate kite program write zero record impairment charge million intangible asset periodically review change fact circumstance result reduction estimate useful life asset require acceleration amortization note goodwill intangible asset note consolidated financial statement include item annual report additional information impairment charge related indefinitelive iprd intangible asset legal contingency party legal action significant describe note commitment contingency legal proceeding note consolidated financial statement include item annual report possible determine outcome matter recognize accrual action extent conclude loss probable reasonably estimable accrue good estimate loss range estimate range well accrue minimum range determine loss reasonably possible loss range loss estimate disclose possible loss significant judgment require determination probability determination exposure reasonably estimable inherent uncertainty unpredictability relate matter accrual base believe good information available time assessment include legal fact circumstance case status proceeding applicable law view legal counsel final resolution matter possible loss excess record amount material adverse effect result operation cash flow financial position periodically reassess matter additional information available adjust estimate assumption fact circumstance indicate need change material accrual consolidated balance sheet matter december income taxis estimate income tax provision include defer tax asset liability base significant management judgment evaluate realization portion defer tax asset quarterly basis record valuation allowance reduce defer tax asset amount likely realize consider future taxable income ongoing tax planning strategy historical financial performance assess need valuation allowance expect realize defer tax asset previously record valuation allowance reduce valuation allowance period determination subject income taxis unite states foreign jurisdiction include ireland economic political condition country actively consider change exist tax law example united states enact significant tax reform certain provision new law continue significantly affect predict form time potential legislative change material adverse impact result operation addition significant judgment require determine worldwide provision income taxis record liability relate uncertain tax position accordance guidance clarifie accounting uncertainty income taxis recognize enterprise financial statement prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return adverse resolution uncertain tax position period material impact result operation period note income taxis note consolidated financial statement include item annual report additional information balance sheet arrangement balance sheet arrangement define item aii regulation sk contractual obligation contractual obligation represent future cash commitment relate significant enforceable legally bind obligation certain purchase obligation likely continue regardless fact cancelable expect timing payment amount present estimate base exist contract reflect future modification termination exist contract anticipate potential new contract follow table summarize aggregate maturity contractual obligation december payment period million total debt operating lease obligation purchase obligation transition tax payable total debt include principal future interest payment senior unsecured note term loan facility interest payment fix rate senior unsecured note incur calculate base term relate note debt include liability relate future royalty obligation assume acquisition immunomedic note acquisition note debt credit facility note consolidated financial statement include item annual report additional information note lease note consolidated financial statement include item annual report additional information amount primarily relate active pharmaceutical ingredient api minimum purchase commitment certain inventoryrelate item rd commitment capital commitment significant rd commitment relate clinical study perform contract research organization cro exclude table material cro contract cancelable connection tax reform record federal income tax payable transition tax mandatory deem repatriation foreign earning payable eightyear period amount include table represent remain federal income tax payable december december longterm income taxis payable include unrecognized tax benefit interest penalty total billion high degree uncertainty time future cash settlement event extinguish unrecognized tax benefit unable estimate period cash settlement exclude unrecognized tax benefit table commit potential future milestone payment party license collaboration development arrangement payment agreement generally contingent certain future event include achievement certain developmental regulatory commercial milestone achievement event probable reasonably estimable potential payment record consolidated balance sheet include table consideration payment approximately billion cash approximately billion acquisition myr gmbh expect close end quarter exclude table note acquisition note consolidated financial statement include item annual report additional information recent accounting pronouncement information require item include note organization summary significant accounting policy note consolidated financial statement include item annual report item quantitative qualitative disclosure market risk expose market risk result change foreign currency exchange rate interest rate credit risk market price reduce certain risk enter type foreign currency interest rate derivative hedging transaction follow investment guideline monitor outstanding receivables risk management program foreign currency exchange risk operation country worldwide result financial result significantly affect factor change foreign currency exchange rate weak economic condition foreign market distribute product operating result expose change foreign currency exchange rate dollar foreign currency significant euro dollar strengthen currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative amount sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business approximately product sale denominate foreign currency partially mitigate impact change currency exchange rate net cash flow foreign currency denominate sale enter foreign currency exchange forward option contract hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay general market risk contract offset correspond gain loss transaction hedge december open foreign currency forward contract notional amount billion billion respectively hypothetical adverse movement foreign currency exchange rate compare dollar relative exchange rate december resulted reduction fair value contract approximately million million respectively date realize negatively affect earning remain life contract analysis consider impact hypothetical change foreign currency exchange rate anticipated transaction foreign currency sensitive instrument design offset interest rate risk portfolio availableforsale debt security senior unsecured note create exposure interest rate risk respect investment portfolio adhere investment policy require limit amount invest security base credit rating maturity industry group investment type issuer security issue government goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return follow table summarize expect maturity average interest rate interestgenerate asset interestbeare liability december expect maturity total fair million percentage total value asset availableforsale debt security average interest rate liability senior unsecured fix rate note include current portion average interest rate senior unsecured float rate note term loan include current portion average interest rate amount represent principal balance addition senior unsecured fix rate note billion fiveyear revolve credit facility mature june amount outstanding fiveyear revolve credit facility december note debt credit facility note consolidated financial statement include item annual report additional information market price risk hold share common stock certain publicly trade biotechnology company primarily connection license collaboration agreement equity security measure fair value change fair value recognize earning fair value equity security approximately billion billion december respectively change fair value equity security impact volatility stock market change general economic condition factor hypothetical increase decrease stock price equity security increase decrease fair value december approximately million million respectively item financial statement supplementary datum gilead sciences inc index consolidated financial statement supplementary data year end december content report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement income consolidate statement comprehensive income consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement report independent register public accounting firm stockholder board director gilead sciences inc opinion financial statement audit accompany consolidated balance sheet gilead sciences inc company december relate consolidated statement income comprehensive income stockholder equity cash flow year period end december relate note collectively refer consolidated financial statement opinion consolidated financial statement present fairly material respect financial position company december result operation cash flow year period end december conformity generally accept accounting principle audit accordance standard public company accounting oversight board united states pcaob companys internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission framework report date february express unqualified opinion thereon basis opinion financial statement responsibility company management responsibility express opinion company financial statement base audits public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audit obtain reasonable assurance financial statement free material misstatement error fraud audits include perform procedure assess risk material misstatement financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation financial statement believe audits provide reasonable basis opinion critical audit matter critical audit matter communicate matter arise current period audit financial statement communicate require communicate audit committee relate account disclosure material financial statement involve especially challenge subjective complex judgment communication critical audit matter alter way opinion consolidated financial statement take communicate critical audit matter provide separate opinion critical audit matter account disclosure relate government commercial rebate description matter fully describe note company estimate reduction revenue amount payable payer healthcare providers united states government commercial rebate program period relate sale occur rebate vary product payer individual payer plan know point sale estimate reduction revenue base product sale historical expect payer mix discount rate estimate actual datum adjust current period expectation auditing company estimate reduction revenue rebate complex involve significant judgment particularly assess reasonableness estimate payer mix apply sale period estimate rely heavily historical datum adjust change payer mix expectation time address evaluate test design operating effectiveness company internal control management estimation matter audit review reduction revenue rebate program include control assess payer mix assumption test completeness accuracy datum utilize control accuracy calculation support management estimate test management estimation methodology determine payer mix audit procedure include evaluate evidence contrary estimate amount perform sensitivity analysis rate estimate perform comparison actual payment relate amount accrue current prior year valuation inprocess research development intangible asset description matter december company inprocess research development iprd intangible asset acquisition prior billion discuss note intangible asset indefinite useful life relate purchase iprd project measure respective fair value acquisition date consider indefinitelive completion abandonment associate rd effort company test indefinitelive intangible asset impairment annual basis annual test aware event change indicate fair value asset carry amount auditing impairment test complex significant judgment require estimate fair value iprd intangible asset particular fair value estimate require use valuation methodology sensitive significant assumption eg discount rate project research development cost probability technical success addressable patient population project market share product profitability affect expect future market economic condition address evaluate test design operating effectiveness company internal control determination matter audit estimate fair value iprd intangible asset example test control management review valuation methodology significant assumption develop fair value estimate test management control validate datum fair value estimate complete accurate test estimate fair value company iprd intangible asset audit procedure include evaluate company use appropriate valuation methodology assistance valuation specialist perform sensitivity analysis determine assumption great impact overall determination value test completeness accuracy underlie datum audit procedure significant assumption include compare assumption current industry market economic trend historical result company business guideline company industry relevant factor example evaluate probability technical success consider phase development iprd project company history obtain regulatory approval valuation intangible asset acquire business combination description matter describe note october company complete acquisition immunomedics inc immunomedic billion cash consideration transaction account business combination acquisition method accounting acquisition date fair value acquire finitelive intangible asset comprise commercial product right indefinitelive intangible asset comprise iprd intangible asset estimate billion billion respectively probabilityweighte income approach discount expect future cash flow present value auditing acquisition date fair value intangible asset acquire immunomedics complex significant judgment require estimate fair value asset particular fair value estimate require use valuation methodology sensitive significant assumption eg discount rate project research development cost probability technical success addressable patient population treatment duration project market share product profitability affect expect future market economic condition address evaluate test design operating effectiveness company internal control determination matter audit estimate fair value intangible asset example test control management review valuation methodology significant assumption develop fair value estimate intangible asset test management control validate datum fair value estimate complete accurate test estimate fair value company intangible asset acquire immunomedics audit procedure include evaluate company use appropriate valuation methodology assistance valuation specialist perform sensitivity analysis determine assumption great impact overall determination value test completeness accuracy underlie datum develop assumption audit procedure significant assumption include compare significant assumption current industry market economic trend historical result company business guideline company industry relevant factor example evaluate probability technical success consider phase development clinical project company history obtain regulatory approval addition evaluate expect addressable patient population compare company estimate external industry forecast ernst young llp serve company auditor san jose california february gilead sciences inc consolidated balance sheet december millions share amount asset current asset cash cash equivalent shortterm marketable security account receivable net inventory prepay current asset total current asset property plant equipment net longterm marketable security intangible asset net goodwill longterm asset total asset liability stockholder equity current liability account payable accrue government rebate accrue liability current portion longterm debt obligation net total current liability longterm debt net longterm income taxis payable longterm obligation commitment contingency note stockholder equity prefer stock par value share share authorize outstanding common stock par value share authorize share issue outstanding respectively additional paidin capital accumulate comprehensive income retain earning total gilead stockholder equity noncontrolle interest total stockholder equity total liability stockholder equity accompany note gilead sciences inc consolidated statement income year end december millions share amount revenue product sale royalty contract revenue total revenue cost expense cost good sell research development expense acquire inprocess research development expense sell general administrative expense total cost expense income operation interest expense income expense net income income taxis income tax expense benefit net income net loss income attributable noncontrolle interest net income attributable gilead net income share attributable gilead common stockholder basic share share calculation basic net income share attributable gilead common stockholder dilute share share calculation dilute accompany note gilead sciences inc consolidated statement comprehensive income year end december millions net income comprehensive income loss net foreign currency translation gain loss net tax availableforsale debt security net unrealize gain net tax reclassification net income net tax net change cash flow hedge net unrealized gain loss net tax reclassification net income net tax net change comprehensive income loss comprehensive income loss comprehensive income loss attributable noncontrolle interest comprehensive income loss attributable gilead accompany note gilead sciences inc consolidated statement stockholders equity millions share amount gilead stockholder equity accumulate common stock additional total paidin comprehensive retain noncontrolle stockholder million share amount share capital income loss earning interest equity balance december cumulative effect adoption new accounting standard change noncontrolle interest net income comprehensive income net tax issuance employee stock purchase plan issuance equity incentive plan stockbase compensation repurchase common stock dividend declare share balance december cumulative effect adoption new accounting standard net income loss comprehensive income net tax issuance employee stock purchase plan issuance equity incentive plan stockbase compensation repurchase common stock dividend declare share balance december cumulative effect adoption new accounting standard note change noncontrolle interest note net income loss comprehensive income loss net tax issuance employee stock purchase plan issuance equity incentive plan stockbase compensation repurchase common stock dividend declare share balance december accompany note gilead sciences inc consolidated statement cash flow year end december million operating activity net income adjustment reconcile net income net cash provide operating activity depreciation expense amortization expense stockbase compensation expense defer income taxis net gain loss equity security acquire inprocess research development expense inprocess research development impairment writedown slow move excess raw material work process inventory change operate asset liability account receivable net inventory prepaid expense account payable income taxis payable accrue liability net cash provide operating activity invest activity purchase marketable debt security proceed sale marketable debt security proceed maturitie marketable debt security acquisition include inprocess research development net cash acquire purchase equity security capital expenditure net cash provide investing activity financing activity proceed debt finance net issuance cost proceed issuance common stock repurchase common stock repayment debt obligation payment dividend net cash provide financing activity effect exchange rate change cash cash equivalent net change cash cash equivalent cash cash equivalent begin period cash cash equivalent end period supplemental disclosure cash flow information interest pay net amount capitalize income taxis pay accompany note gilead sciences inc note consolidated financial statement organization summary significant accounting policy overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatene illness world operation country worldwide headquarters foster city california gileads primary area focus include hiv viral hepatitis cancer seek add exist portfolio product internal discovery clinical development program product acquisition inlicense strategic collaboration portfolio market product include ambisome atripla biktarvy cayston complera descovy descovy prep emtriva epclusa eviplera genvoya harvoni hepsera jyseleca letairis odefsey ranexa sovaldi stribild tecartustm trodelvy truvada truvada prep tybost veklury vemlidy viread vosevi yescarta zydelig approval status jyseleca vary worldwide jyseleca approve united states sell distribute authorize generic version epclusa harvoni united states separate subsidiary asegua therapeutics llc addition sell distribute certain product corporate partner collaborative agreement basis presentation accompany consolidated financial statement include account gilead whollyowne subsidiary certain variable interest entity primary beneficiary intercompany transaction eliminate consolidated entity expose economic record net income loss attributable noncontrolle interest consolidate statement income equal percentage economic ownership interest retain entity respective noncontrolle party assess primary beneficiary variable interest entity vie inception arrangement reporting date assessment base power direct activity vie significantly impact vie economic performance obligation absorb loss right receive benefit vie potentially significant vie segment information operating segment primarily focus discovery development commercialization innovative medicine area unmet medical need chief executive officer ceo chief operating decisionmaker manage allocate resource operation company entitywide basis manage allocate resource entitywide basis enable ceo assess overall level resource available well deploy resource function research development rd project base unmet medical need necessary reallocate resource internal rd portfolio external opportunity good support longterm growth business note revenue summary disaggregate revenue product geographic region significant accounting policy estimate judgment preparation consolidated financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate significant accounting policy estimate base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source estimate assess period update reflect current information economic consideration relate impact recent coronavirus disease covid significant accounting estimate actual result differ significantly estimate reclassification begin acquire inprocess research development iprd expense report separately research development expense consolidate statement income acquire iprd expense consolidate statement income reflect iprd impairment initial cost externally develop iprd project acquire directly transaction business combination alternative future use include upfront payment relate collaboration initial cost right iprd project consolidate statement income year end december conform separately present acquire iprd expense consolidate statement cash flow year end december conform separately present acquire iprd expense exclusive iprd impairment comparative amount consolidate statement cash flow year end december material change income operation operate cash flow result reclassification revenue recognition product sale recognize revenue product sale control product transfer generally shipment delivery customer certain case correspond sale customer party revenue recognize net estimate government rebate chargeback cash discount prompt payment distributor fee sale return provision relate deduction deduction product sale refer grossto net deduction estimate record period relate product sale occur payment term customer generally range day payment term differ jurisdiction customer instance type product variable consideration include net sale price extent significant reversal cumulative revenue recognize probable occurring uncertainty associate variable consideration subsequently resolve expect contract inception period transfer control correspond payment customer year adjust consideration effect significant financing component gross net deduction rebate chargeback government rebate chargeback include amount payable payer healthcare provider program vary product payer individual payer plan rebate chargeback base contractual arrangement statutory requirement vary product payer individual payer plan qualified program purchase product wholesaler distributor low contractual price wholesaler distributor charge difference acquisition cost low contractual price rebate chargeback estimate primarily base product sale expect payer mix discount rate require significant estimate judgment additionally develop estimate consider historical estimate payer mix statutory discount requirement contractual term historical claim experience processing time lag estimate patient population know market event trend market research channel inventory datum obtain major wholesaler pertinent internal external information assess update estimate quarter reflect actual claim current information government chargeback payable direct customer generally classify reduction account receivable consolidated balance sheet government rebate payable party payer healthcare provider record accrue government rebate consolidated balance sheet cash discount estimate cash discount base contractual term historical customer payment pattern expectation future customer payment pattern distributor fee inventory management agreement significant wholesaler pay wholesaler fee primarily compliance certain contractually determine covenant maintenance agree inventory level distributor fee base contractually determine fix percentage sale allowance sale return allowance estimate sale return customer record period relate revenue recognize typically permit return product damage defective customer united states typically permit return month prior year product expiration date outside united states return allow certain country limit basis estimate sale return base primarily analysis historical product return pattern industry information report return rate similar product contractual agreement term consideration know expect change marketplace specific product shipping handle shipping handling activity consider fulfillment activity consider separate performance obligation royalty contract revenue royalty revenue recognize period obligation satisfied correspond sale corporate partner occur research development expense rd expense consist primarily personnel cost include salary benefit stockbase compensation clinical study perform contract research organization cro material supply payment collaborative arrangement include milestone payment license option fee expense reimbursement collaboration partner overhead allocation consist support infrastructure cost upfront milestone payment thirdparty collaborator expense incur point regulatory approval milestone payment regulatory approval capitalize amortize remain useful life relate product time time enter development collaboration agreement share expense collaborative partner record payment receive collaborative partner share development cost reduction research development expense charge rd cost include clinical study cost expense incur clinical study cost significant component rd expense clinical study perform thirdparty cro monitor level performance significant contract include extent patient enrollment activity communication cro accrue cost clinical study perform cro service period specify contract adjust estimate require base ongoing review level effort cost actually incur cro material cro contract terminable write notice generally liable actual service complete cro certain noncancelable expense incur point termination payment research development service prior service render record prepay asset consolidate balance sheet expense service provide sell general administrative expense sell general administrative sga expense relate sale marketing finance human resource legal administrative activity sga expense consist primarily personnel cost facility overhead cost outside marketing advertising legal expense general administrative cost sga expense include brand prescription drug bpd fee united states pharmaceutical manufacturer brand drug product require pay portion bpd fee estimate base select government sale prior year percentage total industry government sale expense cost advertising include promotional expense incur advertising expense million million million year end december respectively cash cash equivalent consider highly liquid investment insignificant interest rate risk original maturity month purchase date cash equivalent marketable nonmarketable security marketable debt security determine appropriate classification marketable debt security time purchase reevaluate designation balance sheet date marketable debt security consider availableforsale carry estimate fair value report cash equivalent shortterm marketable security longterm marketable security unrealize gain loss availableforsale debt security exclude net income report accumulate comprehensive income loss aoci separate component stockholder equity income expense net include interest amortization purchase premium discount realize gain loss sale security expect credit loss cost security sell base specific identification method regularly review investment decline fair value amortize cost basis determine impairment creditrelate factor noncreditrelate factor review include creditworthiness security issuer number security unrealize loss position severity unrealize loss intent sell security likely require sell security recovery amortize cost basis determine portion unrealize loss expect credit loss recognize loss income expense net correspond allowance carry value security hold portion unrealize loss relate factor credit loss recognize aoci marketable nonmarketable equity security investment equity security equity method investment record fair market value fair value readily determinable unrealized gain loss include income expense net consolidated statement income investment entity significant influence meet requirement consolidation elect fair value option use equity method accounting share underlie income loss entity report income expense net consolidated statement income elect fair value option account equity investment galapagos nv galapagos significant influence believe fair value option well reflect underlying economic investment note collaboration arrangement additional information equity security readily determinable fair value record measurement alternative cost impairment adjust observable price change orderly transaction identical similar investment issuer certain investment equity security nonpublic company account equity method base ownership percentage factor indicate significant influence investee note collaboration arrangement additional information investment equity securities record prepay current asset longterm asset consolidate balance sheet regularly review security indicator impairment concentration risk subject credit risk portfolio cash equivalent marketable security investment policy limit amount invest security credit rating maturity industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale trade account receivable record net allowance wholesaler chargeback relate government program cash discount prompt payment credit loss estimate allowance credit loss consider number factor include exist contractual payment term individual customer circumstance historical payment pattern customer review local economic environment potential impact expect future customer payment pattern government funding reimbursement practice majority trade account receivable arise product sale united states europe japan material writeoff charge allowance year end december certain raw material component utilize operation obtain single supplier certain raw material utilize operation facility supplier key component raw material name new drug application file food drug administration fda product significant delay occur qualification new supplier require delivery material supplier interrupt reason unable ship commercial product supply product candidate clinical trial inventory inventory record low cost net realizable value cost determine firstin firstout basis periodically review inventory identify obsolete slow move excess unsaleable item obsolete slow move excess unsaleable item observe alternate use inventory record writedown net realizable value charge cost good sell consolidated statement income determination net realizable value require judgment include consideration factor estimate future product demand product net selling price current future market condition potential product obsolescence future commercialization consider probable future economic benefit expect realize base management judgment capitalize prelaunch inventory cost prior regulatory approval number factor consider include current status regulatory approval process potential impediment approval process safety efficacy anticipate rd initiative impact indication compound viability commercialization marketplace trend property plant equipment property plant equipment state cost accumulate depreciation amortization depreciation amortization recognize straightline method repair maintenance cost expense incur estimate useful life year generally follow description estimate useful life building improvement short year useful life laboratory manufacturing equipment office computer equipment leasehold improvement short useful life lease term lease january adopt accounting standard update topic lease require lessee recognize rightofuse asset lease liability operating lease lease term great year adopt topic modify retrospective method result report period begin january present topic prior period amount adjust continue report accordance historical accounting topic lease determine arrangement contain lease inception rightofuse asset lease liability recognize commencement date base present value lease payment lease term noncancelable period state contract adjust option extend terminate reasonably certain exercise option rightofuse asset adjust prepay lease payment lease incentive initial direct cost incur operating lease expense minimum lease payment recognize straightline basis lease term account lease nonlease component lease agreement single lease component determine lease asset liability addition recognize rightofuse asset liability lease lease term year operating lease provide implicit interest rate generally utilize collateralized incremental borrowing rate apply portfolio approach relevant base information available commencement date determine lease liability acquisition account business combination acquisition method accounting generally require asset acquire include iprd project liability assume record fair value acquisition date consolidate balance sheet excess consideration fair value net asset acquire record goodwill determination estimate fair value require significant estimate assumption result record adjustment fair value asset acquire liability assume measurement period year acquisition date correspond offset goodwill transaction cost associate business combination expense incur determine net asset acquire meet definition business combination acquisition method accounting transaction account acquisition asset goodwill record contingent consideration payment achievement developmental regulatory commercial milestone generally recognize acquisition date asset acquisition upfront payment allocate iprd project acquisition date subsequent milestone payment charge expense consolidated statement income alternative future use goodwill intangible asset goodwill represent excess consideration transfer estimate fair value asset acquire liability assume business combination intangible asset measure respective fair value acquisition date subject adjustment measurement period year acquisition date intangible asset relate iprd project consider indefinitelive completion abandonment associate rd effort amortize goodwill intangible asset indefinite useful life goodwill indefinitelive intangible asset test impairment annually frequently event change circumstance indicate likely asset impair development successfully complete generally occur regulatory approval obtain associate asset deem finitelived amortize respective estimate useful life begin point time intangible asset finite useful life amortize estimate useful life primarily straightline basis review impairment fact circumstance indicate carry value asset recoverable impairment longlive asset longlive asset include property plant equipment finitelive intangible asset review impairment fact circumstance internally externally indicate carry value asset recoverable indication impairment test recoverability compare estimate undiscounted future cash flow expect result use asset carrying asset asset group asset asset group determine impair excess carrying value asset asset group estimate fair value recognize impairment loss valuation contingent consideration result business combination connection certain acquisition require pay future consideration contingent achievement specify development regulatory approval salesbase milestone event record contingent consideration result business combination fair value acquisition date quarter revalue obligation record increase decrease fair value rd expense consolidated statement income time relate product candidate receive marketing approval increase decrease fair value contingent consideration liability result update assumption expect timing probability achieve specify milestone change project revenue change discount rate significant judgment employ determine assumption acquisition date subsequent period update assumption significant impact result operation give period actual result differ estimate foreign currency translation transaction gain loss hedge contract nonus entity operation record functional currency entity result operation nonus dollar functional currency entity translate dollar average currency rate asset liability translate currency rate period end foreign currency translation adjustment record component aoci stockholder equity foreign currency transaction gain loss record income expense net consolidated statement income net foreign currency transaction gain loss material year end december hedge portion foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward contract general market risk relate contract offset correspond gain loss hedge transaction credit risk associate contract drive change interest currency exchange rate result vary time work major bank closely monitor current market condition seek limit risk counterpartie contract unable perform seek limit risk loss enter contract permit net settlement maturity overall risk loss event counterparty default limit unrealize gain outstanding contract ie contract positive fair value date default enter derivative contract trading purpose fair value financial instrument apply fair value account financial asset liability nonfinancial asset liability recognize disclose fair value financial statement recur basis define fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date determine fair value measurement asset liability require record fair value consider principal advantageous market transact marketbase risk measurement assumption market participant use price asset liability risk inherent valuation technique transfer restriction credit risk derivative financial instrument recognize derivative instrument asset liabilitie fair value consolidate balance sheet change fair value derivative designate hedge transaction record period current earning aoci change fair value derivative hedge transaction record period current earning assess inception ongoing basis derivative hedging transaction effective offset change cash flow fair value hedge item determine forecast transaction probable occur discontinue hedge accounting affect portion hedge instrument relate unrealized gain loss contract recognize income expense net consolidated statement income income taxis income tax provision compute liability method defer tax asset liability determine base difference financial statement tax basis asset liability enact tax rate effect year difference expect reverse significant estimate require determine provision income taxis estimate base interpretation applicable tax law regulation record liability relate unrecognized tax benefit accordance guidance clarifie accounting uncertainty income taxis recognize enterprise financial statement prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return adverse resolution uncertain tax position period material impact result operation period elect account tax global intangible lowtaxed income gilti enact tax cut job act tax reform component tax expense period tax incur period cost method significant accounting policy significant accounting policy describe remain appropriate note consolidated financial statement recently adopt accounting pronouncement june financial accounting standard board fasb issue accounting standard update asu financial instrumentscredit loss measurement credit loss financial instrument modify standard asus collectively topic topic require measurement recognition expect credit loss financial asset january adopt standard modify retrospective approach adoption material impact consolidate financial statement connection adoption topic accounting policy election measure allowance credit loss accrue interest receivable november fasb issue accounting standard update collaborative arrangement topic clarify interaction topic topic asu asu clarifie certain transaction participant collaborative arrangement account topic revenue contract customer counterparty customer addition update preclude entity present consideration transaction collaborative arrangement customer revenue counterparty customer transaction january adopt standard apply retrospectively january initially adopt topic adoption impact consolidate financial statement revenue disaggregation revenue revenue follow year end december year end december year end december million europe international total europe international total europe international total product sale hiv product atripla biktarvy compleraeviplera descovy genvoya odefsey stribild truvada hiv revenue share symtuza total hiv product sale hepatitis c virus hcv product ledipasvirsofosbuvir sofosbuvirvelpatasvir hcv total hcv product sale veklury cell therapy product yescarta tecartus total cell therapy product sale trodelvy product ambisome letairis ranexa vemlidy viread zydelig total product sale total product sale royalty contract revenue total revenue include emtriva tybost represent revenue cobicistat c emtricitabine ftc tenofovir alafenamide taf symtuza darunavircftctaf fix dose combination product commercialize janssen sciences ireland unlimited company amount consist sale harvoni authorize generic version harvoni sell separate subsidiary asegua therapeutics llc amount consist sale epclusa authorize generic version epclusa sell separate subsidiary asegua therapeutics llc include vosevi sovaldi include cayston hepsera jyseleca revenue major customer follow table summarize revenue customer individually account total revenue year end december percentage total revenue amerisourcebergen corporation cardinal health inc mckesson corporation revenue recognize performance obligation satisfy prior period revenue recognize performance obligation satisfy prior year relate royalty license intellectual property million million year end december respectively variable consideration include net sale price extent significant reversal cumulative revenue recognize probable occurring uncertainty associate variable consideration subsequently resolve estimate assess period update reflect current information change estimate variable consideration relate sale prior year result million increase million increase revenue year end december respectively contract balances contract asset consist unbilled amount primarily arrangement license intellectual property predominant performance obligation total million million december respectively contract liability million million december respectively revenue recognize include contract liability balance begin respective year material revenue expect recognize future contract liability relate performance obligation satisfy expect material year fair value measurement determine fair value financial nonfinancial asset liability fair value hierarchy establish level input measure fair value follow level input include quote price active market identical asset liability level input include observable input level input quote price similar asset liability quote price identical similar asset liability market active input observable corroborate observable market datum substantially term asset liability marketable security review trading activity pricing measurement date sufficient quote price identical security available use market pricing observable market input similar security obtain thirdparty datum provider input represent quote price similar asset active market derive observable market datum level input include unobservable input support little market activity significant fair value underlie asset liability level asset liability include fair value measurement determine pricing model discount cash flow methodology similar valuation technique significant management judgment estimation financial instrument consist primarily cash cash equivalent marketable debt security account receivable foreign currency exchange contract equity security account payable shortterm longterm debt cash cash equivalent marketable debt security certain equity security foreign currency exchange contract report respective fair value consolidate balance sheet equity security readily determinable fair value record measurement alternative cost impairment adjust observable price change orderly transaction identical similar investment issuer shortterm longterm debt report amortize cost consolidate balance sheet remain financial instrument report consolidated balance sheet amount approximate current fair value follow table summarize type asset liability measure fair value recur basis level fair value hierarchy december december millions level level level total level level level total asset availableforsale debt security treasury security certificate deposit government agency security nonus government security corporate debt security residential mortgage assetbacke security equity security equity investment galapago money market fund publicly trade equity security defer compensation plan foreign currency derivative contract total liability defer compensation plan foreign currency derivative contract total equity investment measure fair value exclude table limit partnership equity method investment million million december respectively equity investment readily determinable fair value million million december respectively amount include longterm asset consolidate balance sheet change fair value equity security result net unrealized loss billion net unrealized gain billion year end december respectively include income expense net consolidated statement income follow table summarize classification equity security consolidate balance sheet million december december cash cash equivalent prepay current asset longterm asset total availableforsale debt security classify cash equivalent shortterm marketable security longterm marketable security consolidate balance sheet note availableforsale debt security additional information note collaboration arrangement additional information equity investment galapago level input estimate fair value level instrument take consideration valuation obtain thirdparty pricing service pricing service utilize industry standard valuation model include incomebase marketbase approach significant input observable directly indirectly estimate fair value input include report trade brokerdealer quote similar security issuer credit spread benchmark security prepaymentdefault projection base historical datum observable input substantially foreign currency derivative contract maturity month time horizon counterpartie minimum credit rating equivalent sp global rating moodys investors service inc fitch ratings inc estimate fair value contract take consideration valuation obtain thirdparty valuation service utilize incomebase industry standard valuation model significant input observable directly indirectly input include foreign currency exchange rate london interbank offer rate swap rate input applicable observable commonly quote interval total estimate fair value aggregate shortterm longterm senior unsecured note term loan facility determine level input base quote market value approximately billion billion december respectively carry value billion billion december respectively level input measure asset acquire liability assume fair value nonrecurre basis connection acquisition immunomedics inc immunomedics note acquisition additional information connection collaboration equity arrangement enter separately pionyr immunotherapeutics inc pionyr tizona therapeutics inc tizona measure fair value exclusive option acquire remain outstanding capital stock pionyr tizona nonrecurre basis note collaboration arrangement additional information measure iprd intangible asset acquire connection acquisition kite pharma inc kite fair value nonrecurre basis recognize pretax impairment charge million million respectively fair value acquire iprd asset estimate base probabilityadjuste discount cash flow calculation level fair value measurement input include estimate revenue cost probability technical regulatory success discount rate amount capitalize iprd subject impairment testing completion abandonment associate rd effort note goodwill intangible asset additional information level liabilitie contingent consideration liability material december policy recognize transfer level classification actual date event change circumstance cause transfer transfer level level level period present availableforsale debt security follow table summarize availableforsale debt security december december gross gross gross gross amortize unrealize unrealized estimate amortize unrealize unrealized estimate million cost gain loss fair value cost gain loss fair value treasury security certificate deposit government agency security nonus government security corporate debt security residential mortgage asset back security total follow table summarize classification availableforsale debt security consolidate balance sheet million december december cash cash equivalent shortterm marketable security longterm marketable security total accrue interest receivable exclude fair value amortize cost basis availableforsale debt security million million december respectively record prepay current asset consolidate balance sheet writeoff accrue interest receivable year end december follow table summarize availableforsale debt security contractual maturity december millions amortize cost fair value year year year year total follow table summarize availableforsale debt security unrealize loss position month month great total gross gross gross unrealize estimate unrealized estimate unrealized estimate million loss fair value loss fair value loss fair value december corporate debt security hold total position unrealize loss position december respectively aggregate gross unrealized loss availableforsale corporate debt security material accordingly impairment recognize year end december gross realize gain gross realize loss availableforsale debt security material year end december derivative financial instrument operation foreign country expose market risk associate foreign currency exchange rate fluctuation dollar foreign currency primarily euro manage risk hedge portion foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward option contract general market risk relate contract offset correspond gain loss hedge transaction credit risk associate contract drive change interest currency exchange rate result vary time hedge exposure foreign currency exchange rate fluctuation certain monetary asset liability denominate nonfunctional currency derivative instrument use hedge exposure designate hedge result change fair value record income expense net consolidated statement income hedge exposure foreign currency exchange rate fluctuation forecast product sale denominate nonfunctional currency derivative instrument use hedge exposure designate cash flow hedge maturity month execute hedge contract quarterly assess hedge effectiveness regression analysis unrealize gain loss aoci reclassify product sale respective hedge transaction affect earning majority gain loss relate hedged forecast transaction report aoci december expect reclassify product sale month cash flow effect derivative contract year end december include net cash provide operating activity consolidate statement cash flow notional amount foreign currency exchange contract outstanding total billion billion december respectively derivative contract allow right offset asset liability present amount gross basis follow table summarize classification fair value derivative instrument consolidate balance sheet december asset derivative liability derivative fair fair million classification value classification value derivative designate hedge foreign currency exchange contract prepay current asset accrue liability foreign currency exchange contract longterm asset longterm obligation total derivative designate hedge derivative designate hedge foreign currency exchange contract prepay current asset accrue liability total derivative designate hedge total derivative december asset derivative liability derivative fair fair million classification value classification value derivative designate hedge foreign currency exchange contract prepay current asset accrue liability foreign currency exchange contract longterm asset longterm obligation total derivative designate hedge derivative designate hedge foreign currency exchange contract prepay current asset accrue liability total derivative designate hedge total derivative follow table summarize effect foreign currency exchange contract consolidate financial statement year end december million derivative designate hedge gain loss recognize aoci gain loss reclassify aoci product sale derivative designate hedge gain loss recognize income expense net time time discontinue cash flow hedge result record relate amount income expense net consolidated statement income discontinuance cash flow hedge year present december hold foreign currency exchange contract follow table summarize potential effect offset foreign currency exchange contract consolidate balance sheet gross amount offset consolidated balance sheet amount assetsliabilitie gross amount gross amount offset present derivative recognize consolidated consolidated balance financial cash collateral net million assetsliabilitie balance sheet sheet instrument receivedpledge legal offset december derivative asset derivative liability december derivative asset derivative liability acquisition seven inc seven april acquire issue outstanding common stock seven clinicalstage immunooncology company focus develop therapy target cancer immune evasion pathway specific cell target approach price share cash total consideration billion net acquire cash result seven whollyowne subsidiary seven lead program magrolimab investigational monoclonal antibody clinical development treatment myelodysplastic syndrome acute myeloid leukemia nonhodgkin lymphoma solid tumor account transaction asset acquisition lead asset magrolimab represent substantially fair value gross asset acquire acquisition date record billion charge represent acquire iprd asset alternative future use acquire inprocess research development expense consolidate statement income connection acquisition record million asset acquire primarily consist defer tax asset liability assume material record stockbase compensation expense million relate cash settlement unveste seven employee stock award attributable postacquisition service primarily record research development expense consolidate statement income year end december immunomedic september enter agreement plan merger agreement plan merger acquire immunomedics company focus development antibodydrug conjugate adc technology immunomedics research develop biopharmaceutical product particularly antibodybase product patient solid tumor blood cancer manufacture market trodelvy trodelvy tropdirecte adc develop immunomedic adc fda approve treatment adult patient metastatic triplenegative breast cancer mtnbc october acquisition complete immunomedic whollyowne subsidiary gilead financial result immunomedic include consolidated financial result year end december date acquisition immunomedic contribute million revenue immaterial net loss date acquisition december cash consideration acquisition billion consist billion cash payment outstanding immunomedic common stockholder million cash payment equity award holder immunomedics vest equity award accelerate vest stockbased award attributable precombination period finance acquisition majority proceed september senior unsecured note offer additional billion borrow new senior unsecured term loan facility cash hand note debt credit facility additional information acquisition immunomedic account business combination acquisition method accounting method require thing asset acquire liability assume generally recognize fair value acquisition date fair value estimate asset acquire liability assume base valuation information know knowable date filing change assumption estimate cause impact valuation asset acquire include intangible asset goodwill relate tax impact acquisition legal contingency amount recognize finalized information necessary complete analysis obtain later year acquisition date record sharebased compensation expense million relate cash settlement accelerate sharebased compensation expense attributable post combination period primarily record sell general administrative expense research development expense consolidate statement income year end december record acquisitionrelate expense million primarily represent closing cost relate fee sell general administrative expense consolidate statement income year end december follow table summarize fair value asset acquire liability assume acquisition date million cash cash equivalent inventory intangible asset finitelive intangible asset acquire iprd outlicense contract defer income taxis liability relate future royalty asset liability net total identifiable net asset goodwill total consideration transfer inventory fair value stepup adjustment million include inventory million acquisition date primarily determine estimate selling price finish inventory cost complete manufacturing process sell effort stepup adjustment record cost good sell consolidated statement income inventory sell customer acquisition date intangible asset finitelive intangible asset billion represents estimate fair value trodelvy mtnbc acquisition date fair value determine apply income approach unobservable input estimate probabilityweighte net cash flow attributable trodelvy mtnbc discount rate discount rate represent estimate rate market participant use value intangible asset intangible asset amortize estimate useful life year acquire intangible asset relate iprd consist trodelvy hormone receptor positive hr human epidermal growth factor receptor negative metastatic breast cancer trodelvy nonsmall cell lung cancer nsclc trodelvy urothelial cancer estimate aggregate fair value billion acquisition date determine apply income approach unobservable input estimate probabilityweighte net cash flow attributable asset discount rate discount rate represent estimate rate market participant use value intangible asset significant assumption inherent development intangible asset fair value include timing project future cash flow include revenue cost sale research development cost sale marketing expense probability success discount rate select measure inherent risk future cash flow assessment asset life cycle competitive trend impact asset factor intangible asset relate iprd project consider indefinitelive asset completion abandonment associate rd effort record intangible asset relate license supply agreement party enter immunomedic prior acquisition agreement party grant exclusive license develop commercialize trodelvy certain territory asia certain sale milestone royalty payment acquisition date fair value million determine estimate probabilityweighte net cash flow attributable outlicense discount rate discount rate represent estimate rate market participant use value intangible asset intangible asset amortize estimate useful life year straightline basis input value identifiable intangible unobservable consider level fair value measurement disclosure guidance defer income taxis net defer tax liability base difference estimate book basis tax basis net asset acquire estimate final preacquisition net operating loss immunomedics liability relate future royalty assume liability relate funding arrangement originally enter immunomedics rpi finance trust delaware statutory trust rpi prior completion acquisition immunomedic funding agreement rpi right receive certain royalty amount subject certain reduction base net sale trodelvy calendar quarter term agreement approximately acquisition date fair value liability estimate billion primarily determine base current estimate future royalty payment rpi life arrangement real option method effective annual interest rate liability amortize effective interest rate method result recognition interest expense year estimate timing future expect royalty payment estimate term reassess reporting period impact change estimate recognize liability relate interest expense prospectively input valuation liability unobservable consider level fair value measurement disclosure guidance liability relate future royalty categorize debt primarily include longterm debt net consolidated balance sheet note debt credit facility additional information goodwill excess consideration transfer fair value asset acquire liability assume billion record goodwill primarily reflect future economic benefit arise asset acquire individually identify separately recognize goodwill recognize immunomedic expect deductible income tax purpose supplemental pro forma information follow pro forma information present combine result operation gilead immunomedics acquisition immunomedic complete january adjustment effect pro forma event directly attributable acquisition year end december millions unaudite total revenue net income loss attributable gilead primary adjustment include postcombination compensation expense million relate acceleration unvested sharebase awards immunomedics ii impact additional interest expense connection immunomedics acquisition borrowing liability relate future royalty iii amortization finitelive intangible asset relate trodelvy mtnbc begin april receive fda accelerate approval iv amortization acquire immunomedics inventory relate trodelvy mtnbc period inventory expect sell begin april v amortization license supply agreement party estimate useful life year vi impact sale marketable security base use source liquidity fund acquisition vii acquisitionrelate transaction cost unaudite pro forma financial result reflect operating efficiency potential cost saving result consolidation operation gilead immunomedic accordingly unaudite pro forma financial result present informational purpose necessarily indicative actual result operation combine company acquisition occur begin indicative future result operation myr gmbh myr december enter definitive agreement pursuant expect acquire myr german biotechnology company approximately billion cash approximately billion foreign currency exchange rate december payable closing transaction potential future milestone payment million approximately million foreign currency exchange rate december fda approval hepcludex payment subject customary adjustment myr focus development commercialization therapeutic treatment chronic hepatitis delta virus hdv acquisition provide gilead hepcludex conditionally approve european medicine agency ema july treatment chronic hdv infection adult compensate liver disease consummation transaction subject expiration termination waiting period hartscott rodino antitrust improvement act receipt merger control foreign direct investment approval certain european jurisdiction certain customary closing condition anticipate closing transaction occur end quarter expect acquisition myr account business combination acquisition method account closing inventory follow table summarize inventory december million raw material work process finish good total report inventory longterm asset total amount report longterm asset primarily consist raw material december total inventory december include fair value adjustment result immunomedics acquisition recognize future period note acquisition additional information inventory write charge year end december material year end december record inventory write charge million million relate slow move excess raw material work process inventory primarily low long term demand hcv product year end december record inventory write charge million million relate excess raw material primarily sustained decrease demand harvoni property plant equipment follow table summarize property plant equipment net december million land land improvement building improvement include leasehold improvement laboratory manufacturing equipment office computer equipment construction progress subtotal accumulate depreciation amortization total unamortized capitalize software cost include office computer equipment million million december respectively capitalize interest construction inprogress include property plant equipment interest capitalize material longlive asset net book value property plant equipment office computer equipment united states billion december billion december billion december corresponding international location million december million december million december individual international location account total balance goodwill intangible asset goodwill follow table summarize change carry goodwill million balance december goodwill result acquisition immunomedics balance december perform annual goodwill impairment assessment fourth quarter early impairment indicator exist december accumulate goodwill impairment loss intangible asset follow table summarize intangible asset net december december gross foreign currency gross foreign currency carry accumulate translation net carry carry accumulate translation net carry million amortization adjustment amortization adjustment finitelive asset intangible asset sofosbuvir intangible asset axicabtagene ciloleucel dlbcl intangible asset trodelvy mtnbc total finitelived asset indefinitelive asset iprd total intangible asset include indefinitelive asset iprd recognize immunomedics acquisition october note acquisition additional information aggregate amortization expense relate finitelive intangible asset billion billion billion year end december respectively primarily include cost good sell consolidated statement income amount capitalize iprd subject impairment testing completion abandonment associate rd effort perform quantitative impairment testing iprd intangible asset probabilityweighte income approach discount expect future cash flow present value discount rate iprd impairment charge record perform quantitative impairment testing iprd intangible asset probabilityweighte income approach discount expect future cash flow present value estimate net cash flow discount discount rate base estimate weightedaverage cost capital company profile similar profile represent rate market participant use value intangible asset discount cash flow model value intangible asset require use level fair value measurement input include estimate revenue cost probability technical regulatory success comparison assessment low estimate revenue change estimate market opportunity new therapy combination exist therapy approve low estimate revenue reduce fair value iprd intangible asset primarily related axicabtagene ciloleucel treatment indolent bcell nonhodgkin lymphoma inhl carrying value result recognition impairment charge million record research development expense consolidate statement income conclude kite program justify effort base totality clinical datum gather discontinue program result carry value iprd relate kite program write zero record impairment charge million research development expense consolidate statement income follow table summarize estimate future amortization expense associate finitelive intangible asset december million total financial information account receivable net follow table summarize account receivable net december millions account receivable chargeback cash discount allowance credit loss account receivable net accrue liability follow table summarize component accrue liability december millions compensation employee benefit income taxis payable allowance sale return accrue expense total collaboration arrangement continue pursue license strategic collaboration similar arrangement party equity investment party focus development commercialization certain product product candidate arrangement involve party active participant operating activity collaboration expose significant risk reward depend commercial success activity arrangement include nonrefundable upfront payment expense reimbursement payment option acquire certain right contingent obligation potential development regulatory milestone payment andor salesbase milestone payment royalty payment revenue profitshare arrangement costshare arrangement arcus biosciences inc arcus acquire million share common stock arcus publicly trade oncologyfocused biopharmaceutical company approximately million secondary equity offering separately enter transaction arcus include entry option license collaboration agreement arcus collaboration agreement common stock purchase agreement investor right agreement subsequently amend arcus stock purchase agreement closing arcus collaboration agreement arcus stock purchase agreement july upfront payment million acquire approximately million additional share arcus common stock million accordance term arcus collaboration agreement arcus stock purchase agreement total million initial cash payment agreement direct transactional cost record million equity investment calculate base arcus close stock price closing date transaction record equity investment arcus longterm asset consolidate balance sheet investment subject contractual lockup provision period year closing date agreement subject certain condition account equity investment arcus fair value change fair value recognize income expense net reporting period remain million attribute acquire license option right million represent iprd asset alternative future use million issuance premium equity purchase million direct transactional cost amounts expense acquire inprocess research development expense year end december consolidate statement income event subsequent december january amend restate common stock purchase agreement pursuant acquire approximately million additional share arcus common stock million february result combine exist share holding million share arcus represent approximately issue outstanding voting stock arcus immediately follow closing transaction gilead right optin current future investigational product candidate emerge arcus research portfolio year follow closing transaction exercise option program arcus opt accord term arcus collaboration agreement company codevelop share global development cost cocommercialize share profit obtain exclusive right commercialize optione program outside subject right arcus exist partner pay arcus tiere royalty range high teen low twenty net sale arcus collaboration agreement subject certain limited exception require provide million arcus second anniversary agreement pay additional million option fourth sixth eighth anniversary agreement terminate early ongoing research development support extend collaboration term year accordingly year end december record million charge represent contractually commit payment acquire inprocess research development expense consolidate statement income arcus collaboration agreement potentially provide billion optin milestone payment respect current clinical product candidate payment trigger arcus collaboration agreement arcus stock purchase agreement right purchase additional share arcus arcus year maximum outstanding voting stock subject threeyear standstill restricting ability acquire voting stock arcus exceeding issue outstanding voting stock arcus subject certain exception additionally agree dispose equity security arcus prior second anniversary closing arcus stock purchase agreement prior consent arcus subject certain exception pionyr june enter transaction pionyr privately hold company pursue novel biology field immunooncology include entry separate merger agreement contemplate initial acquisition equity interest pionyr provide exclusive option subject certain term condition acquire remain outstanding capital stock pionyr pionyr merger option agreement research development service agreement july close transaction pionyr pay million cash accrue additional million payable subject certain customary adjustment pionyr shareholder accordance term pionyr merger option agreement account investment pionyr equity method accounting equity interest provide ability exercise significant influence pionyr investment pionyr consist transaction price note transaction cost exceed prorata portion pionyr net asset transaction closing determine result basis difference primarily relate pionyr iprd alternative future use pionyr business define asc business combination result immediately record charge basis difference million acquire inprocess research development expense consolidate statement income year end december estimate fair value exclusive option acquire remain outstanding capital stock pionyr approximately million base probability weight option pricing model unobservable input consider level fair value measurement disclosure guidance estimate record longterm asset consolidate balance sheet anniversary closing date choose exercise exclusive option purchase remain equity interest pionyr current shareholder million option exercise fee billion potential future milestone payment achievement certain development regulatory milestone case subject certain negotiate adjustment option purchase expire follow early occurrence specify event include delivery datum follow completion certain phase b trial pionyr research development service agreement initial cash funding million record charge acquire inprocess research development expense consolidate statement income year end december addition commit provide additional payment million pionyr achievement certain development milestone accrue million milestone payment relate initiation phase study charge research development expense consolidate statement income year end december subsequently february milestone cash payment million tizona july enter transaction tizona privately hold company develop cancer immunotherapy include entry separate merger agreement contemplate initial acquisition equity interest tizona provide exclusive option subject certain term condition acquire remain outstanding capital stock tizona tizona merger option agreement development agreement august close transaction tizona pay million cash tizona shareholder accordance term tizona merger option agreement account investment tizona equity method accounting equity interest provide ability exercise significant influence tizona investment tizona consist transaction price note transaction cost exceed prorata portion tizona net asset transaction closing determine result basis difference primarily relate tizonas iprd alternative future use tizona business define asc business combination result year end december immediately record charge basis difference million acquire inprocess research development expense consolidate statement income estimate fair value exclusive option acquire remain outstanding capital stock tizona approximately million base probability weight option pricing model unobservable input consider level fair value measurement disclosure guidance estimate record longterm asset consolidate balance sheet anniversary closing date choose exercise exclusive option purchase remain equity interest tizonas current shareholder billion include option fee potential future milestone payment achievement certain development regulatory milestone case subject certain negotiate adjustment option purchase expire follow early occurrence specify event include delivery datum follow completion certain phase b trial tizona development agreement commit provide fund tizona million record acquire inprocess research development expense consolidate statement income year end december tango therapeutics inc tango august enter transaction tango privately hold company pursue innovative target immune evasion therapie patient cancer proprietary crisprenable functional genomic target discovery platform include entry amend restate research collaboration license agreement stock purchase agreement tango collaboration stock purchase agreement enter transaction upfront payment million million equity investment tango represent approximately issue outstanding voting stock tango immediately follow transaction accordance term tango collaboration stock purchase agreement year end december record million upfront expense acquire inprocess research development expense consolidate statement income equity investment tango record cost impairment adjust observable price change orderly transaction identical similar investments tango tango collaboration stock purchase agreement gilead right option program sevenyear collaboration million program optin extension milestone payment product tango opt codevelop copromote party equally split profit loss development cost products tango opt codevelop copromote pay tango low double digit tiere royalty net sale provide tango milestone payment royaltie sale outside jounce therapeutics inc jounce september enter transaction jounce publicly trade company develop novel cancer immunotherapy include entry license registration right stock purchase agreement jounce license stock purchase agreement october close transaction total payment million accordance term jounce license stock purchase agreement record million equity investment longterm asset consolidate balance sheet represent approximately issue outstanding voting stock jounce immediately follow transaction calculate base jounce close stock price closing date transaction year end december record million upfront expense acquire inprocess research development expense consolidate statement income addition provide million future potential clinical regulatory commercial milestone payment achievement certain milestone pay jounce royalty range high single digit midteen base worldwide sale subject certain adjustment galapagos filgotinib collaboration close license collaboration agreement galapago clinicalstage biotechnology company base belgium development commercialization filgotinib jakselective inhibitor evaluate inflammatory disease indication filgotinib agreement closing upfront license fee payment equity investment galapago subscribe million new ordinary share galapagos price share equity investment net issuance premium million amend term filgotinib agreement agree amend term term filgotinib agreement amend agreement obtain exclusive worldwide royaltybearing sublicensable license filgotinib product contain filgotinib december galapagos eligible receive potential future development regulatory milestonebase payment million salesbase milestone payment million plus tiere royalty global net sale range exception certain cocommercialization territory profit shared equally cocommercialization territory uk germany france italy spain belgium netherlands luxembourg share global development cost filgotinib equally termination agreement countrybycountry basis depend circumstance include expiration royalty term cocommercialization territory sale generic product material breach party terminate entire agreement cause follow certain period december follow type meeting fda discuss point raise complete response letter relate new drug application filgotinib treatment rheumatoid arthritis gilead galapagos agree amend agreement galapago assume development manufacturing commercialization certain right filgotinib europe phase transition include transfer filgotinib marketing authorization galapago party intend transfer activity december complete transition december transfer subject applicable local legal regulatory consultation requirement begin january galapagos bear development cost certain study lieu equal cost split contemplated agreement commercial economic filgotinib europe transfer galapagos january subject payment tiere royalty net sales europe gilead start connection amendment agreement gilead agreed irrevocably pay galapagos million approximately million subject certain adjustment higher budget development cost total gilead pay million approximately million january pay additional million approximately million pay million approximately million accrue liability charge research development expense consolidate statement income year end december addition galapagos long eligible receive future milestone payment relate filgotinib europe periods present payment galapagos development cost milestone material global collaboration august close option license collaboration agreement galapago collaboration agreement subscription agreement galapagos subscription agreement galapago pursuant party enter global collaboration cover galapago current future product portfolio filgotinib closing pay billion license option right million new ordinary share galapagos subscription price share fair value billion include issuance discount million calculate base galapago close stock price date closing galapago subscription agreement remain billion payment record acquire inprocess research development expense consolidate statement income year end december pursuant galapagos subscription agreement issue warrant confer right subscribe time time number new share issue galapagos sufficient bring number share own issue outstanding share time exercise exercise warrant subscribe million ordinary share galapago share purchase share open market aggregate fair value million bring number share own million approximately share issue outstanding equity investment galapago initially classify longterm asset consolidate balance sheet subject contractual lockup provision subject year standstill restrict ability acquire voting security galapago exceed issue outstanding voting security galapago agree prior consent galapago dispose equity security galapago prior second anniversary closing galapago subscription agreement dispose equity security galapago fifth anniversary closing galapago subscription agreement disposal issue outstanding voting security galapago subject certain exception termination event designee appoint galapago board director initial contractual lockup provision certain galapago share expire august correspond equity investment balance million include prepaid current asset consolidate balance sheet december december gilead total investment balance galapago billion billion respectively elect fair value option account equity investment galapago investment mark market earning reporting period base market price galapago share believe fair value option well reflect underlying economic investment year end december record pretax unrealize loss billion relate investment galapago income expense net consolidated statement income decline galapagos stock price note fair value measurement additional information galapago collaboration agreement exclusive license development commercialization glpg phase candidate idiopathic pulmonary fibrosis territory option participate development commercialization galapago current future clinical program enter clinical development year collaboration subject extension certain circumstance exercise option program receipt datum package complete qualifying phase study program certain circumstance phase study glpg receive marketing approval pay galapagos million tiere royalty describe respect program galapagos current future pipeline exercise option program pay million option exercise fee program addition galapago receive tiere royalty range net sale territory galapago product optione include glpg exercise option program party share equally development cost mutually agree commercialization cost incur subsequent exercise option galapago retain exclusive commercialization right optione program european union uk iceland norway lichtenstein switzerland exclusive commercialization right country globally terminate collaboration entirety programby program countrybycountry basis advance notice follow customary termination event galapago deliver datum package respect option participate development commercialization glpg phase b candidate osteoarthritis galapago collaboration agreement decline exercise november addition gilead galapagos announce decision halt isabela phase clinical study glpg february janssen compleraeviplera odefsey enter license collaboration agreement janssen tibotec pharmaceutical develop commercialize fixeddose combination truvada janssen nonnucleoside reverse transcriptase inhibitor rilpivirine combination approve european union sell brand complera eviplera european union agreement amend expand collaboration include product contain janssen rilpivirine emtricitabine tenofovir alafenamide odefsey amend agreement janssen grant exclusive license compleraeviplera odefsey worldwide retain right distribute combination product certain country outside party restrict combine drug drug product similar component compleraeviplera odefsey responsible manufacturing compleraeviplera odefsey lead role registration distribution commercialization product country janssen distribute janssen exercise right codetail combination product country sell party financial provision amendment sell party set price combine product party share revenue base ratio net selling price party component subject certain restriction adjustment retain specify percentage janssen share revenue include major market sale product include product sale janssen share revenue include cost good sell consolidated statement income cost good sell relate janssen share million million million year end december respectively termination agreement product country basis depend circumstance include withdrawal product market material breach party expiry revenue share payment term terminate agreement cause respect country sell product case janssen right sell party country product launch market few year symtuza amend license collaboration agreement janssen develop commercialize fixeddose combination janssen darunavir cobicistat emtricitabine tenofovir alafenamide combination approve european union july september respectively sell brand symtuza term amendment grant janssen exclusive license symtuza worldwide janssen responsible manufacturing registration distribution commercialization symtuza worldwide responsible intellectual property relate cobicistat emtricitabine tenofovir alafenamide gilead compound exclusive supplier gilead compound party restrict combine drug drug product similar component symtuza janssen set price symtuza party share revenue base ratio net selling price party component subject certain restriction adjustment intellectual property license supply obligation relate gilead compound account single performance obligation license deem predominant item revenue share relate recognize share symtuza revenue period correspond sale symtuza janssen occur record share symtuza revenue product sale consolidate statement income primarily supply gilead compound janssen symtuza note revenue additional information revenue recognize period present termination agreement product country basis depend circumstance include withdrawal product market material breach party expiry revenue share payment term janssen terminate agreement cause countrybycountry basis case gilead right sell party countryie product launch market few year janssen terminate entire agreement cause japan tobacco inc japan tobacco japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor country world exclude japan japan tobacco retain right pay royalty base product sale japan agreement responsible seek regulatory approval territory require use diligent effort commercialize elvitegravir treatment hiv infection bear cost expense associate commercialization effort pay royalty japan tobacco base product sale japan tobacco market distribute certain product hiv portfolio japan pay royalty base product sale receive approval stribild genvoya elvitegravircontaine product respectively sale product include product sale royalty japan tobacco base product sale include cost good sell royalty japan tobacco base product sale japan include royalty contract revenue consolidate statement income royalty expense recognize million million million year end december respectively royalty income recognize material period present effective december enter agreement japan tobacco acquire right market distribute certain product hiv portfolio japan expand right develop commercialize elvitegravir include japan responsible marketing product january term agreement pay japan tobacco million cash million pay upfront payment remain million pay recognize intangible asset million reflect estimate fair value marketingrelate right acquire japan tobacco remain million record prepay current asset consolidate balance sheet intangible asset amortize year represent period majority benefit expect derive applicable product hiv portfolio amortization expense classify selling expense record sell general administrative expense consolidate statement income termination agreement product country basis depend circumstance include material breach party expiry royalty payment term terminate entire agreement cause gadeta july enter collaboration arrangement gadeta purchase equity gadeta gadeta shareholder determine gadeta vie primary beneficiary power direct activity gadeta significantly impact economic performance initial consolidation gadeta record million noncontrolle interest primarily reflect acquire intangible asset relate iprd consolidated balance sheet year end december effectively terminate agreement gadeta effective termination cease control interest deconsolidate vie remove related net asset noncontrolle interest million consolidated balance sheet net loss deconsolidation material bristolmyer squibb company bms north america collaboration arrangement bms develop commercialize single tablet regimen contain truvada bmss sustiva efavirenz canada combination sell brand atripla bms structure collaboration joint venture operate limited liability company consolidate december terminate bmss participation collaboration follow launch generic version sustiva sole owner joint venture bms permit commercialize atripla canada entitle receive certain fee base net sale atripla decline annual scale bms supply sustiva cost plus markup threeyear period terminate supply agreement notice period bms notify voluntary termination supply agreement year end december record million million million respectively fee expense cost good sell consolidated statement income europe gilead sciences ireland uc whollyowne subsidiary bms collaboration agreement set forth term condition bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory party form limited liability company consolidate manufacture atripla distribution european territory efavirenz purchase bms bmss estimate net selling price efavirenz european territory party form limited liability company hold marketing authorization atripla european territory start limited number activity jointly manage party long coordinate detail promotional activity european territory responsible manufacturing product distribution inventory management warehouse primary responsibility regulatory activity local subsidiary primary responsibility order fulfillment collection receivables customer relation handle sale return territory bms promote atripla general party share revenue outofpocket expense proportion net selling price component atripla truvada efavirenz december efavirenz purchase bms bmss estimate net selling price efavirenz european territory include inventory consolidate balance sheet september bm elect voluntarily terminate agreement effective march post termination bms permit commercialize atripla european territory entitle receive certain fee base net sale atripla decline annual scale threeyear period follow effective date termination collaboration arrangement individually significant enter collaborative equity investment license arrangement similar arrangement consider individually material record upfront collaboration expense relate arrangement million million million year end december respectively acquire inprocess research development expense consolidate statement income cash payment related equity investment year end december million million million respectively primarily record prepaid current asset longterm asset consolidate balance sheet financial term arrangement require payment achievement developmental regulatory commercial milestone significant future milestone payment reflect consolidated statement income correspond event probable connection regulatory approval milestone payment capitalize intangible asset amortize cost good sell term collaboration arrangement addition require pay significant royalty future sale product relate arrangement commercialize payment amount contingent occurrence future event high degree uncertainty occurrence debt credit facility follow table summarize carry borrowing financing arrangement million december type borrowing issue date date interest rate senior unsecured november february senior unsecured september september senior unsecured march april senior unsecured september september month libor senior unsecured december december senior unsecured september march senior unsecured september september senior unsecured september september senior unsecured september september month libor senior unsecured september september term loan october october variable senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march senior unsecured september october senior unsecured september october senior unsecured september september senior unsecured september september senior unsecured september october senior unsecured december december senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march senior unsecured september october total senior unsecured note term loan facility liability relate future royalty total debt net current portion longterm debt obligation net total longterm debt net senior unsecured note september issue senior unsecured note consist million principal float rate note september million principal float rate note september float rate notes ii billion principal senior note september million principal senior note october billion principal senior note october billion principal senior note october billion principal senior note october term summarize table february repay maturity million principal balance relate senior unsecured note september repay maturity billion principal balance relate senior unsecured note repay billion senior unsecured note maturity january repay billion senior unsecured note prior april maturity senior unsecured fix rate note redeem option redemption price equal great principal note redeem ii sum determine independent investment banker present value remain schedule payment principal interest note redeem exclusive interest accrue date redemption discount redemption date semiannual basis treasury rate plus makewhole premium define indenture senior unsecured fix rate note feature exercisable option redeem note par date range month year prior maturity case accrue unpaid interest require redeem date redemption september float rate note feature exercisable option redeem note par approximately year prior maturity event occurrence change control downgrade rate senior unsecured note investment grade moodys investors service inc sp global rating holder require purchase portion note price equal aggregate principal note repurchase plus accrue unpaid interest date repurchase require comply certain covenant senior unsecured note december violation covenant term loan facility september enter commitment letter group institutional lender provide threeyear senior unsecured term loan facility aggregate principal billion pursuant commitment letter october connection acquisition immunomedic enter term loan credit agreement term loan facility borrow aggregate principal billion term loan facility contain customary representation warranty affirmative negative covenant event default term loan facility bear interest eurodollar rate plus applicable percentage define term loan facility terminate reduce borrow term loan facility time premium penalty liability relate future royalty connection acquisition immunomedic assume liability relate funding arrangement originally enter immunomedic rpi prior completion acquisition immunomedic liability relate future royalty primarily include longterm debt net consolidated balance sheet note acquisition additional information revolve credit facility entered billion fiveyear revolve credit facility agreement mature revolve credit facility june terminate revolve credit facility december amount outstanding revolve credit facility june enter new billion fiveyear revolve credit facility mature june revolve credit facility term substantially similar revolve credit facility revolve credit facility work capital requirement general corporate purpose include limitation acquisition december amount outstanding revolve credit facility revolve credit facility contain customary representation warranty affirmative negative covenant event default december compliance covenant loan revolve credit facility bear interest eurodollar rate plus applicable percentage ii base rate plus applicable percentage define revolve credit facility agreement terminate reduce commitment prepay loan new credit facility time premium penalty contractual maturity finance obligation follow table summarize aggregate future principal maturity senior unsecured note term loan facility december million total interest expense interest expense debt credit facility relate contractual coupon rate amortization debt discount issuance cost million billion billion respectively lease operating lease consist primarily property equipment administrative manufacturing rd activity lease include option extend term year include option terminate lease year lease commencement date december material finance lease operate lease expense include variable cost shortterm lease million million respectively operate lease expense prior lease accounting standard million follow table summarize balance sheet information relate operating lease december millions weight average amount classification rightofuse asset net longterm asset lease liability current accrue liability lease liability noncurrent longterm obligation weight average remain lease term year year weight average discount rate follow table summarize supplemental information relate operating lease year end december million cash pay amount include measurement lease liability rightofuse asset obtain exchange lease liability follow table summarize maturity analysis operating lease liability show aggregate lease payment december million total undiscounted lease payment imputed interest total discount lease payment commitment contingency legal proceeding party legal action significant describe recognize accrual action extent conclude loss probable reasonably estimable accrue good estimate loss range estimate range well accrue minimum range determine material loss reasonably possible loss range loss estimate disclose possible loss possible determine outcome matter note outcome include excess accrual expect material reasonably estimate maximum potential exposure range possible loss material accrual matter describe consolidated balance sheet december litigation relate sofosbuvir acquire pharmasset inc acquisition acquire sofosbuvir nucleotide analog act inhibit replication hcv receive approval fda sofosbuvir know commercially sovaldi sofosbuvir include market hcv product receive number litigation claim sofosbuvir carefully consider claim prior follow acquisition believe merit predict ultimate outcome claim range loss aware patent patent application own party future allege party cover use hcv product party obtain valid enforceable patent successfully prove infringement patent hcv product require pay significant monetary damage predict ultimate outcome intellectual property claim relate hcv product spend continue spend significant resource defend claim litigation idenix pharmaceuticals inc idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii idenix udsg centre national de la recherche scientifique luniversit montpellier ii sue district court district delaware allege commercialization sofosbuvir infringe patent patent prevail phase litigation concern patent supreme court deny idenixs petition certiorari idenix udsg sue district court district massachusetts allege commercialization sofosbuvir infringe patent nos patent patent court transfer massachusetts litigation district court district delaware prior trial idenix commit covenant sue respect claim arise patent relate sofosbuvir withdraw patent trial jury trial hold patent jury find willfully infringe assert claim patent award idenix billion past damage judge invalidated idenixs patent vacate jurys award billion past damage idenix appeal decision court appeal federal circuit cafc october cafc issue opinion affirm trial court decision patent invalid april cafc deny idenixs petition rehear en banc january supreme court deny idenixs petition review make judgment idenix final litigation university minnesota university minnesota university obtain patent patent purport broadly cover nucleosides antiviral anticancer activity university file lawsuit district court district minnesota allege commercialization sofosbuvircontaine product infringe patent believe patent invalid infringe continue commercialization sofosbuvir court grant motion transfer case california file petition inter parte review patent trademark office patent trial appeal board ptab allege assert claim invalid anticipation obviousness ptab institute petition schedule merit hear february district court northern district california stay litigation ptab conclude inter partes review initiate expect occur litigation relate axicabtagene ciloleucel october juno therapeutics inc sloan kettere cancer center collectively juno file lawsuit district court central district california allege commercialization axicabtagene ciloleucel sell commercially yescarta infringe patent patent jury trial hold patent december jury find asserted claim patent valid willfully infringe assert claim patent jury award juno damage amount million upfront payment run royalty october date jurys verdict party file posttrial motion quarter trial judge enter judgment april trial judge affirm jurys verdict enhance past damage maintain royalty future yescarta sale april file appeal seek reverse judgment obtain new trial error trial judge assess accrue liability litigation consolidate financial statement consider factor include legal factual circumstance case jurys verdict district court pre posttrial order current status proceeding applicable law view legal counsel likelihood judgment uphold appeal result review determined accordance applicable accounting standard probable incur material loss result litigation judgment reverse appeal loss expect zero judgment uphold entirety appeal estimate loss fourth quarter approximately billion consist primarily approximately million represent damage yescarta revenue december prejudgment interest thereon ii approximately million represent enhancement past damage iii approximately million royalty yescarta revenue december december estimate loss include postjudgment interest forego estimate material december predict certainty ultimate outcome litigation appeal believe jurys verdict judgment error litigation relate bictegravir viiv healthcare company viiv file lawsuit district court delaware allege commercialization bictegravir sell commercially combination tenofovir alafenamide emtricitabine biktarvy infringe viiv patent patent covering viivs dolutegravir bictegravir structurally different dolutegravir believe bictegravir infringe sole asserted claim patent court set trial date january lawsuit viiv seek billion dollar allege damage comprise viivs lose profit royalty sale bictegravir launch trial viiv calculate damage base cumulative revenue biktarvy launch total billion december addition court find liable infringement expect viiv seek royalty sale trial predict certainty ultimate outcome litigation adverse judgment result substantial monetary damage include viivs lose profit royalty trial goingforward royalty stream future sale viiv file lawsuit federal court canada allege activity relate bictegravir compound infringe viiv canadian patent patent issue shionogi co ltd viiv patent compound patent covering viivs dolutegravir believe bictegravir infringe claim patent january court hold summary trial assess viivs infringement allegation april court determine bictegravir infringe claim patent dismiss case viiv appeal decision argument appeal expect place later november december viiv file lawsuit france germany ireland uk assert relevant national designation european patent ep australia assert australian patent japan assert japanese patent korea assert korean patent nos kr patent relate molecule viiv claim act integrase inhibitor believe bictegravir infringe claim viivs patent file opposition european patent office epo request revocation ep epo hearing schedule file petition korean intellectual property office request invalidation kr follow trial tribunal korean intellectual property trial appeal board find kr invalid viiv appeal decision court germany schedule hearing issue infringement april jurisdiction extent claim viivs patent interpret cover bictegravir believe claim invalid predict ultimate outcome intellectual property claim relate bictegravir litigation relate preexposure prophylaxis august file petition request inter parte review patent nos collectively hhs patent ptab hhs patent assign department health human service hhs purport claim process protect primate host infection immunodeficiency retrovirus administer combination emtricitabine tenofovir tdf prior exposure host immunodeficiency retrovirus process commonly know preexposure prophylaxis prep november department justice file lawsuit district court delaware allege sale truvada descovy use prep infringe hhs patent february ptab decline institute petition inter part review hhs patent april file breach contract lawsuit federal government court federal claim allege violation material transfer agreement mta relate research underlie hhs patent clinical trial agreement cta centers disease control prevention relate prep research predict certainty ultimate outcome litigation matter believe federal government breach mtas cta truvada descovy infringe hhs patent hhs patent invalid prior art description truvada use prep postexposure prophylaxis physician patient claim method year hhs file application patent trial date lawsuit district court delaware set litigation generic manufacturer approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product approve generic manufacturer challenge patent protect product grant nce exclusivity year prior end nce exclusivity period generic manufacturer seek continue seek fda approval similar identical drug abbreviate new drug application anda application form typically manufacturer seek approval generic drug sale generic version product early patent expiration significant negative effect revenue result operation seek approval generic version product nce status generic company submit anda fda year brand product approval start december receive letter lupin ltd apotex inc shilpa medicare ltd sunshine lake pharma co ltd laurus labs natco pharma ltd macleods pharma ltd hetero labs ltd cipla ltd collectively generic manufacturer indicate submit andas fda request permission market manufacture generic version certain tenofovir alafenamide tafcontaine product generic manufacturer seek market generic version odefsey descovy vemlidy generic manufacturer challenge validity patent list orange book associate taf challenge validity orange bookliste patent associate taf file lawsuit generic manufacturer intend enforce defend intellectual property european patent claim party file opposition epo request revocation grant european patent cover sofosbuvir expire epo uphold validity certain claim sofosbuvir patent appeal decision seek restore original claim original oppose party appeal request revocation appeal hearing schedule july party file opposition epo request revocation grant european patent relate sofosbuvir expire epo conduct oral hearing opposition uphold claim original oppose party appeal request revocation party file opposition epo request revocation grant european patent cover taf expire epo upheld validity claim taf patent party appeal decision appeal hearing schedule march party file opposition epo request revocation grant european patent relate taf hemifumarate expire epo upheld validity claim taf hemifumarate patent party appeal decision party file opposition epo request revocation grant european patent cover cobicistat expire epo upheld validity claim cobicistat patent party appeal decision appeal process year epo opposition proceeding confident strength patent predict ultimate outcome opposition unsuccessful defend opposition patent claim narrowed revoke patent protection sofosbuvir taf taf hemifumarate cobicistat european union substantially shorten eliminate entirely patent revoke european patent grant covering compound exclusivity base entirely regulatory exclusivity grant ema lose patent protection compound revenue result operation negatively impact year include succeed year exclusivity lose government investigation relate litigation receive subpoena attorney office northern district california request document relate manufacture quality distribution practice complera atripla truvada viread emtriva hepsera letairis cooperate government inquiry department justice inform decline intervene false claim act lawsuit file employee district court grant department justice motion dismiss plaintiff federal claim april plaintiffs refile california false claim act california retaliation claim superior court california county san mateo july california attorney general decline intervene case state court complaint unseal september file demurrer request superior court dismiss plaintiff claim overrule november seek appeal superior court order overrule demurrer predict ultimate outcome lawsuit believe action merit intend vigorously defend receive voluntary request information attorney office eastern district pennsylvania request information relate reimbursement support offering clinical education program interaction specialty pharmacy sovaldi harvoni receive voluntary request information relate speaker program advisory board hcv hbv product october government inform follow investigation decline intervene false claim act lawsuit notwithstanding government declination relator continue pursue lawsuit relate hbv speaker program advisory board serve second amend complaint november december lawsuit relate hcv sale marketing issue unseal relator indicate intend pursue case gilead predict ultimate outcome lawsuit believe action merit intend vigorously defend receive subpoena attorney office southern district new york request document relate promotional speaker program hiv cooperate inquiry april health choice advocate llc health choice advocate file qui tam lawsuit seal new jersey state court allege violation new jersey false claim act clinical education program sovaldi harvoni hcv hiv patient access program lawsuit seek available relief new jersey false claim act july new jersey attorney general office decline intervene lawsuit complaint unseal health choice advocate file qui tam lawsuit seal texas state court make similar allegation texas medicare fraud prevention act tmfpa lawsuit seek available relief tmfpa october texas attorney general office decline intervene lawsuit complaint unseal health choice advocate previously file lawsuit make similar allegation federal false claim act state false claim act include tmfpa federal court eastern district texas june court enter order dismiss matter prejudice july predict ultimate outcome lawsuit believe action merit product liability name defendant class action lawsuit product liability lawsuit relate viread truvada atripla complera stribild plaintiff allege viread truvada atripla complera andor stribild cause experience kidney bone andor tooth injury lawsuit pende state federal court california delaware florida new jersey missouri involve plaintiff plaintiff case seek damage relief ground allege personal injury economic loss intend vigorously defend action believe case merit predict ultimate outcome plaintiff successful claim require pay significant monetary damage antitrust consumer protection japan tobacco bms johnson johnson inc name defendant class action lawsuit file related drug treat hiv include drug combination antiretroviral therapy japan tobacco dismiss lawsuit favorable court ruling defendant motion dismiss plaintiff allege remain defendant engage conduct restrain competition violation federal state antitrust law state consumer protection law lawsuit consolidate pende district court northern district california lawsuit seek bring claim behalf nationwide class direct purchaser consist largely wholesale endpayor purchaser include health insurer individual patient plaintiff seek damage permanent injunctive relief relief september generic manufacturers cipla ltd cipla usa inc cipla name defendant class action lawsuit file district court northern district california jacksonville police officer fire fighter health insurance trust jacksonville trust behalf endpayor purchaser jacksonville trust claim settlement agreement cipla settle patent dispute relate patent cover emtriva truvada atripla product permit generic entry prior patent expiry violate certain federal state antitrust consumer protection law plaintiff seek damage permanent injunctive relief relief believe case merit predict ultimate outcome plaintiff successful claim require pay significant monetary damage subject permanent injunctive relief award favor plaintiff security litigation immunomedic officer director name defendant putative class action file lawsuit consolidate september plaintiff file consolidated complaint november plaintiffs allege immunomedics individual defendant violate federal security law connection immunomedic biologic license application trodelvy seek certification class shareholder damage relief consolidated lawsuit pende united states district court district new jersey january immunomedics file motion dismiss consolidated complaint deny july believe case merit predict ultimate outcome plaintiff successful claim require pay significant monetary damage matter party legal action arise ordinary course business believe legal action material adverse impact consolidate business financial position result operation commitment normal course business enter firm purchase commitment primarily relate active pharmaceutical ingredient api certain inventory relate item december commitment year approximately billion million million million million amount relate api represent minimum purchase commitment stockholder equity stock repurchase program quarter board director authorize billion stock repurchase program program repurchase open market privately negotiate transaction start repurchase program april quarter board director authorize new billion stock repurchase program program commence completion program purchase program open market privately negotiate transaction december remain authorize repurchase program billion follow table summarize stock repurchase program year end december millions share amount share repurchase retire average price share addition repurchase program program repurchase share common stock withhold employee restrict stock award satisfy applicable tax withholding obligation immaterial exclude table use par value method accounting stock repurchase par value method common stock charge par value share involve excess cost share acquire par value allocate additional paidin capital apic base estimate average sale price issue share excess amount charge retain earning dividend follow table summarize cash dividend declare common stock million share amount dividend share dividend share quarter second quarter quarter fourth quarter total restrict stock performance share award unit dividend equivalent right entitle holder dividend equivalent pay vest share underlie unit february announce board director declare quarterly cash dividend share common stock payment date march stockholders record close business march future dividend subject declaration board director prefer stock million share authorize preferred stock issuable series board authorize determine designation power preference right series prefer stock outstanding december accumulate comprehensive income follow table summarize change aoci component net tax unrealize gain unrealize gain foreign currency loss available loss cash translation net forsale debt flow hedge net million tax security net tax tax total balance january net unrealize gain loss reclassification net income net current period comprehensive income loss balance december net unrealize gain reclassification net income net current period comprehensive income loss balance december net unrealize gain loss reclassification net income net current period comprehensive income loss balance december amount reclassify net income gain loss cash flow hedge record product sale consolidate statement income note derivative financial instrument additional information amount reclassify net income gain loss availableforsale debt security record income expense net consolidated statement income income tax impact allocate component comprehensive income material period present employee benefit provide sharebased compensation form type equitybase award include restrict stock unit rsus performance share award unit psus stock option compensation expense recognize consolidated statement income base estimate fair value award grant date estimate fair value rsus base closing price common stock psus estimate fair value base monte carlo valuation methodology stock price date grant stock option award estimate fair value base blackschole option valuation model equity incentive plan stockholder approve adopt gilead sciences inc equity incentive plan amend plan plan authorize issuance total million share common stock seven acquisition assume seven inc equity incentive plan subsequently amend restate gilead sciences inc equity incentive plan amend restate plan aggregate share issue plan assumption date exceed million share immunomedics acquisition assume immunomedics amend restate longterm incentive plan immunomedic plan refer plan plan plan subsequently merge plan aggregate share issue immunomedics plan assumption date exceed million share note acquisition additional information settlement stock award plan broad base incentive plan provide grant equitybase award include stock option restrict stock unit restrict stock award performance share award employee director consultant december total million share remain available future grant plan stock option plan provide option grant designate nonqualifie incentive stock option stock option grant january nonqualified stock option employee stock option generally vest year option exercisable period exceed contractual term year date stock option issue grant price fair market value common stock grant date stock option exercise settle common stock plan previously authorize available pool share follow table summarize activity relate information stock option plan option grant present table exercise price fair value underlie common stock grant date weight weightedaverage aggregate average remain intrinsic share exercise price contractual term value million dollar year million outstanding december grant forfeit expired exercise outstanding december exercisable december expect vest net estimate forfeiture december aggregate intrinsic value represent value close stock price trading day year excess weightedaverage exercise price multiply number option outstanding exercisable total intrinsic value option exercise million million million weightedaverage grant date fair value stock option grant share share share december million unrecognized compensation cost relate stock option expect recognize estimate weightedaverage period year restrict stock performance share award grant timebase rsus certain employee annual employee equity compensation review program new hire employee nonemployee members board rsus sharebase awards entitle holder receive freely tradable share common stock vest rsus generally vest year date grant fair value rsu equal closing price common stock grant date grant psus vest achievement specify market performance goal include achieve total shareholder return compare predetermine peer group achieve revenue target actual number common share ultimately issue calculated multiplying number psus payout percentage range award generally vest committee subcommittee board determine specify market performance goal achieve fair value psu estimate date grant performance objective define grant depend term award fair value date grant determine base monte carlo valuation methodology closing stock price date grant addition grant psus certain employee plan vest award subject achievement specify individual performance goal typically year period fair value award equal closing price common stock grant date follow table summarize rsu psu activity relate information rsus psus weighted weight average average grant date fair grant date fair million share amount share value share share value share outstanding december grant vest forfeited outstanding december weightedaverage grantdate fair value share exclude share relate grant currently grant date performance objective define weightedaverage grant date fair value rsus grant share share share weightedaverage grant date fair value psus grant share share share total grant date fair value vest rsus psus million million million total fair value respective vest date million million million december million unrecognized compensation cost relate unvested rsus psus expect recognize weightedaverage period year employee stock purchase plan employee stock purchase plan international employee stock purchase plan amend espp employee purchase share common stock base percentage compensation subject certain limit purchase price share equal low fair market value common stock offering date purchase date espp offer sixmonth lookback feature automatic reset feature provide offer period reset new lowerpriced offering offer price new offering period current offering period espp purchase settle common stock espps previously authorize available pool share million share issue espp million total million share common stock authorize issuance espp million share available issuance espp december stockbase compensation follow table summarize total stockbased compensation expense include consolidated statement income year end december million cost good sell research development expense sell general administrative expense stockbase compensation expense include total cost expense income tax effect stockbase compensation expense net tax pretax stockbase compensation expense year end december million include million noncash stockbase expense million million accelerate postacquisition stockbase expense relate acquisition immunomedic seven respectively note acquisition additional information income tax effect year end december include million income tax expense follow court appeal decision altera corp v commissioner require related party intercompany cost sharing arrangement share expense relate stockbased compensation stockbase compensation recognize expense requisite service period consolidate statement income straightline expense attribution approach reduce estimate forfeiture estimate forfeiture base historical experience requisite service period shorter vest period employee retirement eligible valuation assumption fair value option grant plan purchase espp estimate grant purchase date blackschole option valuation model blackschole option valuation model develop use estimate fair value trade option vest restriction fully transferable addition option valuation model require input highly subjective assumption include expect stock price volatility expect award life follow assumption calculate estimate fair value award year end december expect volatility stock option espp expect term year stock option espp riskfree interest rate stock option espp expect dividend yield fair value stock option grant calculate single option approach use blend historical volatility imply volatility trade option common stock determine expect volatility expect term stockbase award represent weightedaverage period award expect remain outstanding estimate weightedaverage expect term base historical cancellation historical exercise datum relate stock option contractual term vest term award riskfree interest rate base observe interest rate appropriate term stockbase award dividend yield base history expectation dividend payout defer compensation maintain retirement saving plan eligible employee defer compensation income tax purpose section k internal revenue code gilead science k plan certain foreign subsidiary maintain define benefit plan require local regulatory requirement total matching contribution expense gilead science k plan define benefit plan million million million maintain deferred compensation plan director key employee defer compensation amount defer participant deposit rabbi trust total asset liability associate defer compensation plan million december million december net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder calculate base weightedaverage number share common stock outstanding period dilute net income share attributable gilead common stockholder calculate base weightedaverage number share common stock dilutive security outstanding period potentially dilutive share common stock result assume exercise outstanding stock option equivalent determine treasury stock method potential share common stock exclude computation dilute net income share attributable gilead common shareholder effect antidilutive million million million respectively follow table show calculation basic diluted net income share attributable gilead common stockholder year end december millions share amount net income attributable gilead share share calculation basic dilutive effect stock option equivalent share share calculation dilute net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder diluted income taxis income loss income taxis consist follow year end december million domestic foreign income income taxis income tax expense benefit consist follow year end december millions federal current deferred state current defer foreign current deferred income tax expense benefit income tax benefit include billion defer tax benefit relate intangible asset transfer foreign subsidiary ireland united states fourth quarter complete intraentity asset transfer certain intangible asset foreign subsidiary ireland transaction result stepup irish taxdeductible basis transfer asset accordingly create temporary difference tax basis exceed book basis intangible asset result recognize defer tax asset billion consolidated financial statement expect able realize defer tax asset result intraentity asset transfer impact intangible asset transfer foreign subsidiary united states material income tax expense include million defer tax charge relate transfer acquire intangible asset foreign subsidiary united states transaction result stepup taxdeductible basis result recognize defer tax liability million temporary difference book basis exceed tax basis acquire intangible asset reconciliation federal statutory tax rate apply income taxis effective tax rate summarize follow year end december federal statutory rate state taxis net federal benefit foreign earning different rate research credit tax foreign earning defer tax intraentity transfer intangible asset settlement tax examination acquire iprd relate charge change valuation allowance nontaxable unrealized gain loss investment effective tax rate defer income taxis reflect net tax effect temporary difference carry amount asset liability financial reporting purpose amount income tax purpose significant component defer tax asset liability follow december millions defer tax asset net operating loss carryforward stockbase compensation reserve accrual currently deductible excess tax basis book basis intangible asset upfront milestone payment research credit carryforward equity investment liability relate future royalty net total defer tax asset valuation allowance valuation allowance total defer tax asset defer tax liability property plant equipment excess book basis tax basis intangible asset total defer tax liability net defer tax asset liability valuation allowance million million december respectively increase valuation allowance primarily relate acquire attribute relate seven immunomedics acquisition unrealize loss equity method investment reflect acquire iprd expense valuation allowance decrease million december million december primarily reduction net operating loss carryforward asset recognition framework correspond valuation allowance respect certain foreign jurisdiction december federal net operating loss tax credit carryforward approximately billion million respectively start expire utilize addition state net operating loss tax credit carryforward approximately billion million respectively state net operating loss start expire utilize state tax credit carryforward start expire utilize utilization net operating loss tax credit subject annual limitation ownership change limitation provide internal revenue code amend similar state provision annual limitation result expiration net operating loss credit utilization file federal state foreign income tax return unite states foreign jurisdiction federal income tax purpose statute limitation open onwards onwards california income tax purpose certain acquire entity statute limitation open year inception utilization net operating loss credit carry prior year income tax return subject audit federal state foreign tax authority currently examination state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position total unrecognized tax benefit billion billion december respectively recognize reduce effective tax rate period recognition interest penalty relate unrecognized tax benefit include income tax expense benefit consolidate statement income million million year end december respectively interest penalty relate unrecognized tax benefit year end december material accrue interest penalty relate unrecognized tax benefit million million december respectively december believe reasonably possible unrecognized tax benefit significantly change month follow rollforward total gross unrecognized tax benefit year end december million balance begin period tax position relate current year addition reduction tax position relate prior year addition reduction settlement lapse statute limitation balance end period select quarterly financial information unaudite million share amount st quarter nd quarter rd quarter th quarter total revenue gross profit product sale net income loss net income loss attributable gilead net income loss share attributable gilead common stockholder basic net income loss share attributable gilead common stockholder dilute total revenue gross profit product sale net income loss net income loss attributable gilead net income loss share attributable gilead common stockholder basic net income loss share attributable gilead common stockholder dilute amount second quarter include acquire iprd expense billion basic diluted share primarily relate acquisition seven note acquisition additional information amount quarter include acquire iprd expense billion basic diluted share relate collaboration investment enter separately arcus pionyr tango tizona million basic diluted share unrealize loss change fair value equity investment largely galapago note fair value measurement note collaboration arrangement additional information amount fourth quarter include million basic diluted share unrealize loss change fair value equity investment largely galapago million basic diluted share acquisitionrelate expense primarily amortization intangible asset inventory stepup charge accelerate stockbased compensation expense relate acquisition immunomedic note fair value measurement note acquisition note collaboration arrangement additional information amount quarter include upfront collaboration licensing expense billion basic diluted share relate collaboration galapago note collaboration arrangement additional information amount fourth quarter include billion favorable tax effect relate intraentity intangible asset transfer million pretax net gain equity security primarily equity investment galapago partially offset million pretax impairment charge relate iprd intangible asset acquire connection acquisition kite pretax writedown charge million slow move excess raw material work process inventory impact factor result net favorable impact basic share diluted share note fair value measurement note inventory note goodwill intangible asset note income taxis additional information item change disagreement accountant account financial disclosure applicable report independent register public accounting firm stockholder board director gilead sciences inc opinion internal control financial reporting audit gilead sciences inc internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission framework coso criterion opinion gilead sciences inc company maintain material respect effective internal control financial reporting december base coso criterion indicate accompany management report internal control financial reporting management assessment conclusion effectiveness internal control financial reporting include internal control immunomedics inc include consolidated financial statement company constitute total asset liability respectively december revenue year end audit internal control financial reporting company include evaluation internal control financial reporting immunomedics inc audit accordance standard public company accounting oversight board united states pcaob consolidate balance sheet company december relate consolidated statement income comprehensive income stockholder equity cash flow year period end december relate note report date february express unqualified opinion thereon basis opinion company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audit accordance standard pcaob standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate ernst young llp san jose california february item control procedure evaluation disclosure control procedure evaluation december carry supervision participation management include chief executive officer chief financial officer effectiveness disclosure control procedure define rule ae securities exchange act amended exchange act control procedure company design ensure information require disclose company report file submit exchange act record process summarize report time period specify security exchange commission rule form information accumulate communicate company management include chief executive officer chief financial officer appropriate allow timely decision require disclosure base evaluation chief executive officer chief financial officer conclude disclosure control procedure effective december b management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule af exchange act internal control system design provide reasonable assurance preparation fair presentation financial statement external purpose accordance generally accept accounting principle internal control system matter design inherent limitation provide reasonable assurance objective internal control system meet supervision participation management include chief executive officer chief financial officer conduct evaluation effectiveness internal control financial reporting base criterion establish committee sponsor organization treadway commission coso internal controlintegrate framework base evaluation conclude internal control financial reporting effective december scope management assessment effectiveness internal control financial reporting exclude immunomedics inc gilead acquire business combination october total asset exclude goodwill intangible asset total liability total revenue immunomedics represent approximately total asset total liability total revenue gilead consolidated financial statement year end december respectively independent register public accounting firm ernst young llp audit consolidated financial statement include item annual report issue report internal control financial reporting december report audit internal control financial reporting appear c change internal control financial reporting management include chief executive officer chief financial officer evaluate change internal control financial reporting occur quarter end december conclude change quarter materially affect reasonably likely materially affect internal control financial reporting item b information applicable iii item director executive officer corporate governance information require item concern director executive officer incorporate reference section definitive proxy statement file securities exchange commission pursuant regulation connection annual meeting stockholder proxy statement heading gilead board director nominees board structure executive officer applicable delinquent section report write code ethic apply director employee include executive officer include limitation principal executive officer principal financial officer principal accounting officer controller person perform similar function code ethic available website httpwwwgileadcom investor section corporate governance intend disclose future amendment certain provision code ethic waivers code ethic grant executive officer director website business day follow date amendment waiver item executive compensation information require item incorporate reference section proxy statement heading executive compensation committee board director compensation committee report compensation nonemployee board member item security ownership certain beneficial owner management relate stockholder matter information require item incorporate reference item annual report head equity compensation plan information section proxy statement head security ownership certain beneficial owner management item certain relationship relate transaction director independence information require item incorporate reference section proxy statement heading gilead board director board process item principal accountant fee service information require item incorporate reference section proxy statement head principal accountant fee service iv item